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ABSTRACT 
Over the past two decades, advances in RNA structural biology have improved our 
understanding of the structures and folding properties of naturally occurring RNAs. RNA 
sequences and structures participate in many specific biological functions, such as those performed 
by messenger RNA (mRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), micro RNA 
(miRNA), short-interfering RNA (siRNA), small nuclear RNA (snRNA) and many others. The 
noncoding RNAs, such as siRNA, do not express proteins but have been utilized in a wide range 
of applications, including RNA interference (RNAi) and the regulation of mRNA expression. 
These important biological functions have been implemented in gene therapy and for screening 
malignant gene targets. In spite of their therapeutic potential, naturally occurring siRNAs are 
limited by poor pharmacological properties which has hindered their translation into the clinic. 
However, recent studies have highlighted the fruitful applications of modified siRNAs, including    
the use of siRNA nanostructures in cancer detection and treatment. In this thesis, the prerequisite 
conditions for forming stable RNA hybrid assemblies are described in Chapter 2. These conditions 
are critically important for the generation of stable higher-order RNA nanostructures. Inspired by 
the widespread biological function of self-assembled RNA hybrids, linear RNA templates and two 
complementary strands were self-assembled in order the determine the requirements for efficient 
RNA hybridization into stable three-component systems (3CS). In this study the RNA sequence 
composition and length were found to impact hybridization and self-assembly. Moreover, buffer 
conditions were also evaluated in order to explore the influence of ionic strength and metal cation 
composition on stable RNA hybridization. The complementary RNAs were annealed in buffer and 
analyzed by native PAGE, thermal denaturation and CD spectroscopy. The data supported the 
stable 3CS self-assembly on a thirty nucleotide (30nt) RNA template and with complementary 
15nt and 23 nt RNA sequences in Tris buffer. These conditions were shown to favor the self-
assembly of higher-order RNA structures, such as the siRNA nanostructures in Chapter 3.  
The genetically encoded, self-assembled siRNA nanostructures targeting the Glucose 
Regulated Proteins (GRP) were developed for applications in siRNA screening of these important 
oncologic targets and for potentiating cancer gene therapy. In our RNAi nanotechnology approach, 
linear, V- and Y-shape RNA templates were synthesized by semi-automated solid phase RNA 
synthesis with the use of a ribouridine branchpoint synthon which was used generate the V- and 
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Y-shape RNA templates. The RNA templates were then hybridized in Tris buffer with their 
complementary strands, in stoichiometric ratios which favored hybridization and self-assembly    
into genetically encoded spheres, triangles, squares, pentagons and hexagons of discrete sizes and 
shapes. The siRNA self-assembly was confirmed by native PAGE while TEM imaging validated 
the sizes and shapes of the siRNA nanostructures. Moreover, thermal denaturation and CD 
spectroscopy were used to ascertain the prerequisite siRNA hybrids for their RNAi applications. 
In a 24 sample siRNA screen conducted within the AN3CA endometrial cancer cells known to 
overexpress tumorigenic GRP78 activity, the self-assembled siRNAs targeting multiple sites of 
GRP78 mRNA demonstrated more potent and long-lasting anticancer activity relative to their 
linear controls. Extending the scope of our RNAi screening approach, the self-assembled siRNA 
hybrids (5 nM) that targeted GRP-75, 78 and 95 were tested within endometrial (AN3CA), cervical 
(HeLa) and breast (MDA-MB-231) cancer cell lines with respect to the control non-cancerous lung 
(MRC5) cell line. The results indicated that the non-cancerous MRC5 lung cell line which 
displayed normal glucose regulated chaperone levels was found to tolerate siRNA treatment and 
demonstrated less toxicity relative to the cancer cells that were found to be addicted to glucose 
regulated chaperome. Therefore, the GRP targeting siRNAs were found to elicit more potent anti-
cancer activity due to an overexpression and strong dependence of GRP activity in cancer. The 
serum stability of the self-assembled siRNAs was also investigated relative to the linear siRNA 
control. The data analyzed on a denaturing PAGE indicated a quick (< 4 h) degradation profile of 
the linear siRNA hybrid while the siRNA nanostructures were disassembled into their native RNA 
templates with no further degradation observed over the course of a 48 h fetal bovine serum (FBS) 
treatment. Thus, the RNA templates have been proposed to contribute to the prolonged (72 h) 
RNAi effect observed within the cancer cells. In sum, these remarkable self-assembled siRNA 
nanostructures may thus encompass a new class of potent siRNAs that may be useful in screening 
important oncogene targets while improving siRNA therapeutic efficacy and specificity in cancer.  
KEYWORDS: siRNA nanostructures, RNAi nanotechnology, cancer gene therapy, Chaperones, 
Glucose Regulated Proteins (GRP), endometrial, cervical and breast cancer 
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CHAPTER 1: INTRODUCTION OF RNA SELF-ASSEMBLY 
AND ITS APPLICATIONS IN CANCER RESEARCH 
1.1 Discovery of RNA Self-assembly 
One of the biggest questions in science is based on the evolution of life on earth, dating 
back to the pre-biotic world that existed on early Earth. Many speculations and conspiracy theories 
that were later proved and disproved by ground breaking research provided an answer to the 
question of whether life originated from RNA or its close relative DNA? Studies on the origin of 
the world have shown that DNA and RNA might have evolved from nucleic acid building blocks 
which may have self-assembled into structures that represents the starting point of the ‘RNA 
World’ hypothesis. In this model, RNA was found to be the original scaffold for storing and 
expressing genetic information into the evolution of life on earth.1 Through evolutionary changes, 
DNA synthesized by polymerases adopted the function as the carrier of genetic information in 
cells due to its more stable structure relative to RNA. The transcription of mRNA described a new 
role for RNA, as an intermediary molecule in between DNA and protein expression. Moreover, 
the creation of polypeptides or proteins by the translational machinery produced new RNAs with 
novel self-assembled architectures and functions inside the cell. These actions have been 
engineered in the laboratory in an effort to mimic the multiple structures and functions of RNA 
inside cells. For example, in vitro engineering of RNAs has led to the development of diverse 
RNAs with varied functions such as transcription, translation, degradation, maturation, and the 
catalytic activity related to the regulation of cellular bio-systems.2 Thus technological 
advancements in RNA synthesis and engineering has led to the development of a wide range of 
synthetic RNAs for their growing applications in biology, biotechnology and medicine.3 
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Furthermore, RNAs are formulated with a wide range of carriers that contributes towards their 
fruitful applications.4  
The varied sequences and self-assembled structures are key to the versatile functions RNA 
can adopt in cells and in vivo. Generally, RNA can be divided into three functional motifs, RNA 
can function as its primary sequence, as well as within its secondary and tertiary structures (Figure 
1.1).  The primary sequence of RNA is formed by covalent phosphodiester bonding while the 
secondary and tertiary structures are due to non-covalent Watson-Crick base pairing or hydrogen-
bonding (H-bonding) and pi-stacking interactions (Figure 1.1(A, B, C)).7,8  These RNA sequences 
and structures participate in many specific biological functions, such as those performed by 
messenger RNA (mRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), micro RNA (miRNA), 
short-interfering RNA (siRNA), small nuclear RNA (snRNA) and many others.5,9,10 The linear 
single stranded mRNA sequence functions as a carrier of genetic information, and serves  as a 
template for protein synthesis with the use of additional RNAs that form part of the protein 
translational machinery. These include the secondary RNA self-assembled structures, tRNA, 
which adopts a series of stems and loops in a structure formulation that facilitates amino acid 
loading and transfer to the growing polypeptide. The tRNA forms part of the functional tertiary 
RNA structures, strongly associated with the ribosome and forming part of the catalytic RNA-
protein complex for polypeptide synthesis (Figure 1.1E).11 In a different application, the self-
assembled miRNA and siRNA function to regulate gene expression for important applications in 
biotechnology and in medicine.6 This new RNA application is supported by the fact that while less 
than 2% of the information stored in the entire human genome is designated for protein coding, 
more than 80% is transcribed into RNAs with still unspecified functions.12 RNA structural motifs 
are routinely used as modules in a variety of combinations to code for distinctive and specialized 
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architectures that enable specific operations such as intermolecular recognition, catalytic, or 
mechanical functions. RNA thus provides functional self-assemblies for applications in 
nanotechnology. 7,13-17  
 
Figure 1.1 RNA primary, secondary and tertiary bonding interactions. (A) The primary bond 
formed by covalent phosphodiester linkage between two RNA nucleotides. (B) Watson-Crick 
hydrogen bonding interaction between RNA nucleosides to form RNA secondary and tertiary 
structures. (C) The ᴨ- ᴨ base stacking interaction for RNA stable A-type helix formation. (D) RNA 
pucker confirmation. (E) Various secondary RNA motifs. (F) Secondary and tertiary helical 
structure of tRNA demonstrating coaxial stacking and bonding interaction. (G) Effect of salt on 
stable RNA tertiary structure formation.  
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1.2 Methods of RNA Self-assembly 
Over the past two decades, advances in RNA structural biology have improved our 
understanding of the structures and folding properties of naturally occurring self-folding RNAs. 
RNA self-assembly has led to functional RNAs, including RNA catalysts (ribozymes and 
ribosomes)1,2, RNA receptors (riboswitches), and RNA adaptors (tRNA)2,3. The accumulation of 
knowledge regarding the modularity of RNA architectures also facilitates the number of small 
RNA modules (RNA motifs) that were used for the bottom-up design of artificial RNA structures 
(Figure 1.2). The architectural potential of RNA relies on the ability of a single RNA strand to 
fold into a stable 3D self-assembled structure. Incorporating functional and structural elements 
that could potentially allow the construction of complicated RNA nanomachines is a critical 
requirement for their technological and medical applications. From a structural point of view, the 
2’-OH group in RNA locks the ribose sugar into a C3’-endo chair conformation (Figure 1.1D) 
facilitating the formation of the  A-form RNA double helix, which is about 20% shorter and wider 
than B-form DNA.4 Moreover, the presence of special structural motifs such as bends, stacks, 
junctions, loops and chelates with the presence of metal ions, such as Mg2+, further improves the 
stability and functional utilities of the 3D RNA structures (Figure 1.1G).18-24  Such inspirational 
functional architectures of RNA have ushered in a new era of artificial RNA nanotechnology for 
its applications in the medical as well as the material sciences.  
Within the realm of RNA self-assembly methods there are two main strategies, template 
and non-template self-assembly. Templated assembly involves the interaction of RNA molecules 
under the influence of specific external sequences, forces, or spatial constraints. In contrast, non-
templated assembly involves the formation of larger structures by individual components without 
the influence of external forces. Examples of non-template assembly are related to the ligation, 
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chemical conjugation, covalent linkage, and loop/loop interactions of RNA, especially in the 
formation of RNA multimeric complexes.26-30 Within the context of this thesis, a templated self-
assembly strategy will be discussed. In this application, a single stranded RNA functions as a 
template for the self-assembly of RNA hybrids that may lead to the generation of synthetic 
artificial nanoarchitectures.22,24,30,31,40,42,56,65,70 There are four distinct methods for the templated 
assembly of RNAs, these include:  (1) RNA architectonics, (2) single-strand RNA assembly, (3) 
RNA/DNA hybrid self-assembly, and (4) co-transcriptional assembly (Figure 1.2).  
The concept of RNA tectonics was initially defined as RNA structures that can be 
decomposed and reassembled into new modular RNAs, called RNA tectonics (tectoRNAs).25 This 
strategy recognizes the essential structural components of each RNA strand associated within its 
3D shape. Furthermore, computer assisted 3D design provides a limitless number of self-
assembling RNA units forming synthetic RNA nanostructures that can be generated through a 
tetraloop-receptor interactions and stable hairpin loop-loop dimerization.16,26,31-34 The 
predefined/preorganized artificial RNA nanostructures can be self-assembled by taking advantage 
of thermodynamically stable motifs participating in the canonical Watson-Crick and non-canonical 
base pairing interactions. The shape and makeup of the RNA tectonics have resulted in 120° 
kissing loop motifs found in hexagonal nanorings and HIV kissing loops that resulted in the  
assembly of RNA tectosquares.31,32,35 This strategy has also been applied in the library assembly 
of fibers,36-38 triangles,39-41 squares,31,32,42 hexagons,38,43 polyhedrons,32,35,71 closed-ring 
structures66 and 2D array31,32,40 nanostructures. Thus, RNA tectonics offers the possibility of 
designing structurally complex architectures mimicking large naturally occurring RNA 
nanomachines. 
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Figure 1.2. Self-assembly strategies and other principles governing the design of RNA-based 
functional nanostructures. Grabow, W.W.; Jaeger, L. Acc. Chem. Res. 2014, 47, 1871-1880.  
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 Single strand RNA (ssRNA) assembly in contrast to RNA architectonics relies on 
complementary RNA strands that are unstructured by themselves but when mixed together are 
able to assemble through Watson Crick base pairs. Using base-pairing hybridization properties, 
RNA can also form nanostructures with elementary secondary structure motifs including crossover 
Holiday junctions.39,44-48 Single stranded RNA can be used in conjunction with other strategies to 
promote programmed assembly of RNA units through complementary tail-tail 
interactions.31,32,35,39,47,49 Although, this strategy is limited by mismatches in between bases, which 
can be addressed by computation-based complementary sequence optimization studies.44,46 
Moreover, self-complementarity or systematic repeats can be introduced to form naturally 
occurring nanostructures such as the DsrA and GcvB type arrays in cells.50-53  In a more recent 
study, structurally well-defined RNA tiles by integrating a 90° bend of RNA and artificially 
designed T-junctions have been formed. Sufficient rigidity of the RNA tiles favored homo-
oligomerization into a large and uniform RNA architecture, an octameric cube.65 Another approach 
can be amenable to single stranded self-assembly with the use of hundreds of short (32-nucleotide) 
modular “bricks” (Figure 1.3).53 
The unique properties of RNA and DNA can be integrated for the self-assembly of RNA-
DNA hybrid nanostructures. Conventional Watson Crick base-pairing between RNA and DNA 
readily form helices resulting in a structural bias for the A-type helix. For example, RNA-DNA 
hybrids equipped with a toehold for selective strand displacement allowed the formation of 
functional RNA moieties.54,55 Other examples include the formation of nucleic acid nanoparticles 
as a result of double stranded RNAs (pre-siRNAs) functionalized using DNA self-assembly with 
complementary sticky tails.46,56 Crossover techniques have been developed for the self-assembly 
of large nucleic acid architectures using hundreds of DNA staples to fold long RNA templates into 
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simple shapes, such as ribbons, rectangles, triangles, and RNA templated square tiles. In this 
manner, a self-assembled RNA-DNA hybrid can be used to create well-programmed, stable RNA 
nanostructures having multi-functional utility in the materials and medical sciences.57-60,67  
 The ability of RNA to produce kinetically controlled self-assemblies using the endogenous 
transcription machinery has gained widespread attraction in the formation of bio-synthetic RNA 
nanostructures by coupling RNA synthesis with RNA self-assembly in-vitro or in-vivo.61,46,52,62  
For example, the RNA nanorings employed RNA tectonics and co-transcriptional self-
assembly,61,62 while the RNA nanocubes,46,64 and organelle-like RNA52 scaffolds were generated 
from the co-transcriptional assembly of single-stranded RNA. In addition, rolling circle 
transcription is a distinctive co-transcriptional strategy to form long RNAs (RNA microsponges) 
with periodic repeats resulting in lamellar-like structures.63 On the other hand, RNA 
polymerization enables the construction of complex structures at relatively low cost. For example, 
a transcriptional method has been used to synthesize a long RNA strand which folded into RNA 
nanostructures.68,69 Moreover, RNA polymerases have also been implicated in the self-assembly 
of RNA particles for efficient cellular uptake and biological activity.70  
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Figure 1.3. RNA nanostructures constructed using various RNA self-assembly strategies. (A) 
Several tertiary interactions directing a 90° bend between adjoining helices have been used to 
generate (i−iv) tectosquares31, 32 and (v) antiprism shaped polyhedrons35 including (i, ii) the right 
angle (RA), (iii) UA_h3WJ,31 and (iv, v) tRNA-5WJ31,35 motifs [parts i, ii reproduced from: 
Chworos, A.; Severcan, I.; Koyfman, A.Y.; Weinkam, P.; Oroudjey, E.; Hansma, H.G.; Jaeger, L. 
Science 2004, 306, 2068-2072.; parts iii, iv reproduced from: Severcan, L.; Geary, C.; 
Verzemnieks, E.; Chworos. A.; Jaeger, L. Nano Lett. 2009, 9, 1270-1277.; part v reproduced from: 
Severcan, I.; Geary, C.; Chworos, A.; Voss, N.; Jacoverry, E.; Jaeger, L. Nat. Chem. 2010, 2, 772-
779. (B) Hexagonal nanoparticles38,43 built from the (i) RNAI/IIi kissing loop38 and (ii) the pRNA43 
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[part i reproduced from: Grabow, W. W.; Zakrevsky, P.; Afonin, K.A.; Chworos, A.; Shapiro, 
B.A.; Jaeger, L. Nano Lett. 2011, 11, 878-887.; part ii reproduced from: Zhang, H.; Endrizzi, J.A.; 
Shu, Y.; Haque, F.; Sauter, C.; Shlyakhtenki, L.S.; Lyubchenko, Y.; Guo, P.; Chi, Y.I. RNA 2013, 
19, 1226-1237.] (C) RNA particles and fibers incorporating the HIV KL and A-minor Junction 
[reproduced from: Geary, C.; Chworos, A.; Jaeger, L. Nucleic Acids Res. 2011, 39, 1066-1080.] 
(D) Particles (i) and fibers (ii) using GNRA loop-receptor tectoRNAs [reproduced from: Nasalean, 
L.; Baudrey, S.; Leontis, N.B.; Jaeger, L. Nucleic Acids Res. 2006, 34, 1381-1392.] (E) RNA 
nanoparticles built using the ssRNA strategy: (i) Kink Turn triangle based on two single strands 
(ss) assembling with a protein [reproduced from: Ohno, H.; Kobayashi, T.; Kabata, R.; Endo, K.; 
Iwasa, T.; Yoshimura, S.H.; Takeyasu, K.; Inoue, T.; Saito, H. Nat. Nanotechnol. 2011, 6, 116-
120.]; (ii) 4ss triangle [reproduced from: Bindewald, E.; Afonin, K.; Jaeger, L.; Shapiro, B.A. ACS 
Nano 2011, 5, 9542-9551.]; (iii) IRES nanosquare based on 8ss [reproduced from: Dibrov, S.M.; 
McLean, J.; Parsons, J.; Hermann, T. Proc. Natl. Acad. Sci. USA 2011, 108, 6405-6408.]; (iv) 
RNA nanocubes based on 6ss and 10ss [reproduced from: Afonin, K.A.; Bindewald, E.; 
Yaghoubian, A.J.; Voss, N.; Jacovetty, E.; Shapiro, B.A.; Jaeger, L. Nat. Nanotechnol. 2010, 5, 
676-682.]. Nanostructures have been characterized by atomic force microscopy (AFM), cryo-
electron microscopy (cryo-EM), NMR, or crystallography (X-ray) as indicated.26,31,36 
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1.3 Application of RNA Self-assemblies in Cancer Gene Therapy 
  Decoding the human genome has revealed that a substantial part (~98.5%) of our genetic 
make-up, the so called “junk” DNA, transcribes  noncoding RNAs.72 The noncoding RNAs do not 
express proteins but have been utilized for nanotechnology-based RNA gene therapy. These 
important bio-medical applications includes the use of small interfering RNA (siRNA), micro 
RNA (miRNA) and antisense RNA for the RNAi based mechanism of gene regulation.153 
Moreover, the catalytic RNAs ribozymes, have also been implemented for catalytic gene 
regulation.1,2 The selective ligand binding RNAs, the RNA aptamers have been evolved for the 
detection of cancers. RNA nanotechnology has revolutionized the use of these therapeutic RNAs 
for the detection and therapy (theranostic) applications of cancer.73  
Cancer gene therapy represents one of the most rapidly developing areas in preclinical and 
clinical cancer research. Viral vectors have been used as primary means to deliver genes to target 
cancer cells, although risks associated with toxicity, target specificity, immune and inflammatory 
responses have limited their clinical utility.74 To address the limitations of viral gene transduction 
methods, liposome,75 dendrimers,76,99,100 carbon nanotubes,77 synthetic polymers,78 and gold 
nanoparticles79 have been successfully implemented in gene delivery applications. Current 
advances in cancer gene therapy using multivalent RNA nanoparticles have shown promises to 
combat cancer using siRNA, miRNA, aptamer and with drugs by various methods such as 
conjugation and encapsulation.15,82-85 Hence, RNA nanotechnology allows the self-assembly of 
multifunctional RNA motifs that may be administered into specific cells or tissues for targeted 
cancer therapy. Since the discovery of RNA interference (RNAi)86 based therapy, siRNA, miRNA 
and shRNA have gained attention in the down-regulation of oncogenic protein expression which 
leads to cancer cell death.87 
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Figure 1.4 Schematic representation of siRNA mediated gene silencing via RNAi mechanism. 
Figure adapted from arrowheadpharma.com/science. 
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The RNAi mechanism applied to cancer gene therapy invokes the use of short, non-coding 
RNA hybrids (siRNA/miRNA/shRNA) that have the ability to act as substrates for the RNA 
Induced Silencing Complex (RISC). When bound to RISC, the RNAs are processed into the linear 
antisense RNA sequences by the nuclease activity of the Argonaute enzyme. This linear RNA 
functions as a template for the hybridization of the targeted oncogenic mRNA that is subsequently 
hydrolyzed leading to the inhibition of cancer cell proteins that ultimately lead to cancer cell death 
(Figure 1.4).85-87 This mechanism has led to the development of a wide range of RNA-drug 
candidates for cancer gene therapy applications. The majority of RNAi based drugs are composed 
of multiple siRNA sequences or self-assemblies that can target a single or multiple oncogenic 
mRNAs for potent cancer gene therapy effects. (Table 1.1) Thus, siRNA have been formulated 
into potential cancer drug candidates due to their ability to specifically target oncogenic mRNA 
sequences and silence their protein expression which compromises cancer cell viability.88-92  
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Figure 1.5 siRNA hybrid structures for RNAi activity. Figure has been adapted from: Hong, C.A.; 
Nam, Y.S. Theranostics, 2014, 4, 1211-1232. 
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To date, many RNA nanostructures have been designed to include: 1) identical siRNAs 
targeting the same gene locus; 2) different siRNAs targeting different loci on a single gene; 3) 
different siRNAs targeting different genes, thereby modulating multiple cell signaling pathways 
that generate synergistic or additive responses.93,94 The design and delivery of multiple siRNA 
units for cancer gene therapy has been extensively studied by combining two,95,96 three,97 four,97,98 
and six94,56 siRNAs by template-assisted hybridization into siRNA nanostructures. The design of 
siRNA nano-assemblies requires: 1) optimal siRNA sequence length (19-25 nucleotides with 2-
nucleotide 3’-end overhangs); and 2) siRNA sequence prediction by computer generated softwares 
to prevent off-target mRNA silencing effects. After carefully designing the siRNA antisense and 
sense sequences, the functionalization of RNA into nanoparticle/nanostructure formulations 
requires minimal design steps to prevent any mis-folding of RNA scaffold strands. Additional 
examples of self-assembled RNA nanostructures applied to gene silencing include, the dumbbell-
shaped nanocircular RNAs that have been designed to induce the RNAi. This effect was triggered 
by the Dicer enzyme cleaving activity of long non-coding RNA into active siRNAs for potent and 
long lasting RNAi activity.100-102 Recently, branched RNA, called trimer or tetramer RNA, was 
also adopted to trigger the RNAi response and prolong the gene silencing activity by sterically 
shielding the siRNA from nucleases .96,97 Chimeric DNA/RNA and RNA/pRNA oligomers were 
made and assembled into genetically encoded siRNA dendrimers.76,98,99 
 
The nanoring shaped tectoRNAs have also been self-assembled for the efficient delivery 
of siRNAs that have shown resistance to exonucleases.38,100 Furthermore, by exploiting the 
physical properties of siRNA structure formation, a sponge-like spherical structure referred to as 
an siRNA nano-sheet was synthesized by rolling circle transcription (RCT) and effectively 
processed by Dicer producing multiple siRNA precursors for gene silencing activity.103 Another 
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example involves chimeric DNA/RNA self-assemblies, which employed a tetrahedral DNA 
template carrying six siRNAs. Imaging of the nanoparticles illustrated a DNA tetrahedral scaffold 
that positioned six siRNAs as 3’ overhangs.94  
   
1.4 Challenges, Solutions and Applications of siRNA Nanoparticles in Cancer Gene Therapy  
A number of promising results suggests a great potential of siRNA nanostructures and 
assemblies in cancer treatment. However, a series of challenges remain and limit the full potential 
of translating the siRNA application into the clinic, and most siRNA drug delivery systems are 
still in preclinical studies.  The existing barriers for the successful application of siRNAs in clinical 
cancer therapy includes; nuclease instability which results in short half-lives, limited cell uptake 
that restricts intracellular resident time for potent knockdown effects, off-target gene knockdown 
which leads to toxicity, early/late endosomal escape which restricts therapeutic efficacy, in 
addition to rapid, renal clearance and activation of innate immune responses which limits the 
pharmacological potential of the therapeutic siRNAs. Therefore, siRNA-based cancer gene 
therapy requires the careful design of therapeutics that may overcome these extra- and intra-
cellular barriers and lead to their safe and effective administration for potent therapeutic activity 
(Figure 1.6). 
As mentioned above, the design and chemical modification of siRNAs is an essential 
requirement for improving cancer gene therapy applications.  Chemical modifications allows 
siRNAs to acquire serum stability and prolong their biological activity, while limiting the immune 
response which typically hinders siRNA access to the RNAi machinery.154 Chemical modifications 
can be introduced at the 5’ or 3’ termini of the RNA oligonucleotides, but they may also effect the 
phosphodiester backbone, the ribo-sugar or nucleobase. The most common and essential siRNA 
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modifications alter the 2’-OH of the ribose sugar in order to prevent its involvement in RNA strand 
isomerization and degradation during acid, base or enzyme catalyzed hydrolysis.155 The 2’-O-
methyl (2’-OMe) and 2’-deoxy-2’-fluoro (2’-F) are the most acceptable and well tolerated 
modifications that have enhanced siRNA serum stability and increased their in vivo activity.132 
Other modifications include, backbone changes from the phosphodiester to phosphothioester or 
phosphothioate with and without 2’ modifications.132 Additionally, RNA cyclization has led to the 
generation of the locked nucleic acids (LNAs) that have shown enhanced nuclease stability and 
RNAi activity.132 While other modifications such as boranophosphonate backbone modifications 
have improved nuclease stability but compromised RNAi activity. In order to enhance the RNAi 
activity, the siRNAs have been extended with 3’-overhang sequences by incorporating additional 
–AA or –UU nucleotides at the 3’-terminus. Currently the efficacy of siRNA is limited by its 
delivery methods, hence improvements in the specificity and efficacy of current delivery system 
is a necessary requirement for their clinical applications in cancer gene therapy. Advanced RNA 
nanotechnology can address this limitation by nanoparticle formulations that may potentiate the 
silencing of oncogenic mRNA.  
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Figure 1.6 Barriers encountered by siRNA following their systemic administration. siRNA may 
be degraded in the blood or removed by renal excretion or macrophages. siRNAs may not reach 
their target cells because of electrostatic repulsions with the lipid bilayer. Once internalized, 
siRNAs may be prevented from reaching their intracellular targeted mRNA due to limited escape 
from the endosome-lysosome pathway. Figure has been adopted from:  Liu, X.; Liu, C.; Laurini, 
E.; Posocco, P.; Pricl, S.; Qu, F. Mol. Pharm. 2012, 9, 470-481. 
 
The encapsulation of siRNA within nanoparticles have shown improvements in shielding 
the siRNA from nucleases and immune responses while assisting in siRNA delivery. Furthermore 
ligand bound nanoparticles have been shown to increase the selectivity of siRNA delivery to tumor 
cells leading to the enhanced permeability and retention (EPR) effect.105,106 For example, siRNA 
conjugation with drugs, cationic polymers and targeting ligands have demonstrated improved 
therapeutic utility by enhancing cell permeability and intracellular resident time which potentiates 
the RNAi response. Often, conjugated polymers are hydrophobic in nature which minimizes the 
water solubility of siRNAs thereby limiting their therapeutic potential.156 Conjugation or 
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complexing of hydrophilic polymers with siRNA have been shown to significantly increase 
nanoparticle solubility, stability in biological media and increased oral absorption.107-109 siRNA 
nanoparticles can be formed using biological additives, such as phospholipids110 in addition to 
soft/organic and hard/inorganic materials (Figure 1.7).118,119 Often cyclodextrins114 and other 
synthetic polymers such as poly(lactic-co-glycolic acid) (PLGA)113,115 (either degradable or non-
degradable) with multiple copies of siRNA are formulated covalently or non-covalently into 
nanocarriers such as liposomes, nanoemulsions, and dendrimers that enhance siRNA compatibility 
and reduce cytotoxicity.86,111,112 Several reviews have been published on the delivery of siRNA 
with a wide range of nano-carriers.94,112,115-118 Thus, RNA nanotechnology has been widely applied 
for the therapeutic and diagnostic (theranostic) treatments of cancer.  
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Figure 1.7. The various methods of siRNA formulation within a variety of nanoparticle 
formulations.  Figure has been adapted from: Hong, C.A.; Nam, Y.S. Theranostics, 2014, 4, 1211-
1232. 
 
The shapes and sizes of RNA nanoparticles or nanostructures have also been shown to 
effect its activity in vitro and in vivo.  For example, nanoparticle formulations of different sizes 
and shapes have led to different uptake capacities and half-lives within cells.120-124 Particle sizes 
ranging from 20-120 nm are optimal because they limit elimination or destruction mechanisms 
and immunostimulatory reponses.91,124,154  
Often endocytic pathways are dependent on the sizes of the endocytic vesicles. Gene 
transfection and tissue uptake can be well tolerated if the nanoparticle formulation is uniform and 
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less than 100 nm in size.122,125,126 Surface characteristics of nanoparticles can also impact the 
internalization process via endocytosis or phagocytosis. More often, positive surface charged 
nanoparticles bind strongly to the anionic cell membrane facilitating a higher cellular uptake.122,126 
Considering the extracellular pH of tumors is slightly acidic (pH 6-7) while that of normal cells is 
about pH 7.6 the structural stability of the nanoparticle can be altered based on pH changes, 
allowing for the controlled disassembly of the nanoparticle and release of the siRNA within cancer 
cells.127,128  
The tumor target specificity is another very crucial requirement to avoid off-target toxicity. 
Many studies have been accomplished by covalently and non-covalently conjugating siRNAs with 
targeting ligands such as folate,56,30 proteins113, antibody,139 aptamers,138 peptides135-137 or with 
other polymer attached ligands117,130,131,134,140,141. Currently, many siRNA-based nanoassemblies 
targeting a variety of oncogenes against different cancer types are being evaluated in early-stage 
preclinical and clinical trials. The following table shows some of the ongoing clinical studies for 
siRNA based cancer gene therapy (Table 1.1). Thus, RNA nanoparticle formulations have gained 
widespread utility in pre-clinical and clinical cancer gene therapy. 
 
 
 
 
 
 
 
 
22 
 
 
Table 1.1. siRNA based drugs in the clinical trials.a 
 
aData table adapted from ref 142. Xu, C.; Wang, J. Asian J. Pharma. Sci. 2015, 1, 1-12.  
 
   
 
 
 
 
 
23 
 
 
1.5 REFERENCES. 
1) Joyce, G.F. Annu. Rev. Biochem. 2004, 73, 791-836. 
2) Davidson, E.A; Ellington, A.D. Trends Biotechnol. 2005, 23, 109-112. 
3) Famulok, M; Harting, J.S; Mayer, G. Chem Rev. 2007, 107, 3715-3743. 
4) Keller, M. J. Controlled Release 2005, 103, 537-540. 
5) a) Grabow, W.W.; Jaeger, L. Acc. Chem. Res. 2014, 47, 1872-1880.  
b) Wu, Q.; Huang, L.; Zhang, Y.; Sci. China C. Life Sci. 2009, 52, 232-244. 
c) Moore, P. B.; Steitz, T.A. Cold Spring Harb. Perspect Biol. 2011, 3, a003780. 
d) Cochrane, J.C.; Strobel, S.A. Acc. Chem. Res. 2008, 41, 1027- 1035. 
e) Baird, N.J.; Fang, X.W.; Srividya, N.; Pan, T.; Sosnick, T.R. Q. Rev. Biophys. 2007, 40, 
113-161. 
f) Doherty, E.A.; Doudna, J.A. Annu. Rev. Biophys. Biomol. Struct. 2001, 30, 457-475. 
6) a) Jaeger, L.; Chworos, A. Curr. Opin. Struct. Biol. 2006, 16, 531-543. 
b) Krishnan, Y.; Bathe, M. Trends Cell Biol. 2012, 22, 624-633. 
7) Schroeder, R.; Barta, A.; Semrad, K. Nat. Rev. Mol. Cell Biol. 2004, 5, 908-919. 
8) Lescoute, A.; Westhof, E. Nucleic Acids Res. 2006, 34, 6587-6604. 
9) Collins, L.J.; Penny, D. Trends Genet. 2009, 25, 120-128. 
10) St Laurent, G.; Savva, Y.A. Front. Genet. 2012, 3, 57-64. 
11) Batey, T.R.; Rambo, P.R.; Doudna, A.J. Angew. Chem. Int. Ed. 1999, 38, 2326-2343. 
12) Qu, H.; Fang, X. Genomics, Proteomics Bioinf. 2013, 11, 135-141. 
13) Afonin, K.A.; Lindsay, B.; Shapiro, B.A. RNA Nanotechnol. 2013, 1, 1-15. 
14) Grabow, W.; Jaeger, L. F1000Prime Rep. 2013, 5, 46. 
15) Guo, P. Nat. Nanotechnol. 2010, 5, 833-842. 
16) Ishikawa, J.; Furuta, H.; Ikawa, Y. Wiley Interdiscip. Rev. RNA 2013, 4, 651-664. 
17) Chakraborty, S.; Mehtab, S.; Krishnan, Y. Acc. Chem. Res. 2014, 47, 1710-1719. 
18) Draper, D.E. Biophys. J. 2008, 95, 5489-5495. 
19) Woodson, S.A. Annu. Rev. Biophys. 2010, 39, 61-77. 
20) Leipply, D.; Draper, D.E. Biochemistry 2011, 50, 2790-2799. 
21) Abels, J.A.; Moreno-Herrero, F.; Van der Haijden, T.; Dekker, C.; Dekker, N.H. Biophys. 
J. 2005, 88, 2737-2744. 
22) Barbeyron, R.; Vasseur, J.J.; Smietana, M. Chem. Sci. 2015, 6, 542-548. 
23) Freier, S.M.; Kierzek, R.; Jaeger, J.A.; Sugimoto, N.; Caruthers, M.H.; Neilson, T.; Turner, 
D.H. Proc. Natl. Acad. Sci. USA 1986, 83, 9373-9377. 
24) Kumar, V.; Kumar, A. Methods Mol. Biol. 2015, 1316, 195-210 
25) Westhof, E.; Masguida, B.; Jaeger, L. Fold Des. 1996, 1, 78-88. 
26) a) Jaeger, L.; Leontis, N.B. Angew. Chem. Int. Ed. Engl. 2000, 39, 2521-2524. 
b) Kireeva, L.M.; Komissarova, N.; Kashlev, M. J. Mol. Biol. 2000, 299, 325-335. 
27) Shu, D.; Moll, W.D.; Deng, Z.; Mao, C.; Guo, P. Nano Lett. 2004, 4, 1717-1723. 
28) Guo, S.; Tschammer, N.; Mohammed, S.; Guo, P. Hum Gene Ther. 2005, 16, 1097-1109. 
29) Shu, D.; Huang, L.; Hoeprich, S.; Guo, P. J. Nanotechnol. 2003, 3, 295-302. 
24 
 
30) Khaled, A.; Guo, S.; Li, F.; Guo, P. Nano Lett. 2005, 5, 1797-1808. 
31) Chworos, A.; Severcan, I.; Koyfman, A.Y.; Weinkam, P.; Oroudjey, E.; Hansma, H.G.; 
Jaeger, L. Science 2004, 306, 2068-2072. 
32) Severcan, L.; Geary, C.; Verzemnieks, E.; Chworos. A.; Jaeger, L. Nano Lett. 2009, 9, 
1270-1277. 
33) Jaeger, L.; Chworos, A. Curr. Opin. Struct. Biol. 2006, 16, 531-543. 
34) Bindewald, E.; Hayes, R.; Yingling, Y.G.; Kasprzak, W.; Shapiro, B.A. Nucleic Acids Res. 
2008, 36, 392-397. 
35) Severcan, I.; Geary, C.; Chworos, A.; Voss, N.; Jacoverry, E.; Jaeger, L. Nat. Chem. 2010, 
2, 772-779. 
36) Nasalean, L.; Baudrey, S.; Leontis, N.B.; Jaeger, L. Nucleic Acids Res. 2006, 34, 1381-
1392. 
37) Geary, C.; Chworos, A.; Jaeger, L. Nucleic Acids Res. 2011, 39, 1066-1080. 
38) Grabow, W.W.; Zakrevsky, P.; Afonin, K.A.; Chworos, A.; Shapiro, B.A.; Jaeger, L. Nano 
Lett. 2011, 11, 878-887. 
39) Ohno, H.; Kobayashi, T.; Kabata, R.; Endo, K.; Iwasa, T.; Yoshimura, S.H.; Takeyasu, K.; 
Inoue, T.; Saito, H. Nat. Nanotechnol. 2011, 6, 116-120. 
40) Shu, D.; Moll, W.D.; Deng, Z.; Mao, C.; Guo, P. Nano Lett. 2004, 4, 17171-1723. 
41) Khaled, A.; Guo, S.; Li, F.; Guo, P. Nano Lett. 2005, 5, 1797-1808. 
42) Grabow, W.W.; Zhuang, Z.; Swank, Z.N.; Shea, J.E.; Jaeger, L. J. Mol. Biol. 2012, 424, 
54-67. 
43) Zhang, H.; Endrizzi, J.A.; Shu, Y.; Haque, F.; Sauter, C.; Shlyakhtenki, L.S.; Lyubchenko, 
Y.; Guo, P.; Chi, Y.I. RNA 2013, 19, 1226-1237. 
44) Bindewald, E.; Afonin, K.; Jaeger, L.; Shapiro, B.A. ACS Nano 2011, 5, 9542-9551. 
45) Afonin, K.A.; Ceiply, D.J.; Leontis, N.B. J. Am. Chem. Soc. 2008, 130, 93-102. 
46) Afonin, K.A.; Bindewald, E.; Yaghoubian, A.J.; Voss, N.; Jacovetty, E.; Shapiro, B.A.; 
Jaeger, L. Nat. Nanotechnol. 2010, 5, 676-682. 
47) Dibrov, S.M.; McLean, J.; Parsons, J.; Hermann, T. Proc. Natl. Acad. Sci. USA 2011, 108, 
6405-6408. 
48) Khisamutdinoy, E.F.; Jasinski, D.L.; Guo, P. ACS Nano 2014, 8, 4771-4781. 
49) Koyfman, A.Y.; Braun, G.; Magonov, S.; Chworos, A.; Reich, N.O.; Jaeger, L. J. Am. 
Chem. Soc. 2005, 127, 11886-11897. 
50) Busi, F.; Cayrol, B.; Lavelle, C.; LeDerout, J.; Pietrement, O.; Le Cam, E.; Geinguenaud, 
F.; Lacoste, J.; Regnier, P.; Arluison, V. Cell Cycle 2009, 8, 952-954. 
51) Cayrol, B.; Nogues, C.; Dawid, A.; Sagi, I.; Siberzan, P.; Isambert, H. J. Am. Chem. Soc. 
2009, 131, 17270-17276. 
52) Delebecque, C.J.; Lindner, A.B.; Silver, P.A.; Aldaye, F.A. Science 2011, 333, 470-474. 
53) Ke. Y.; Ong, L.L.; Shih, W.M.; Yin, P. Science 2012, 338, 1177-1183. 
54) Afonin, K.A.; Desai, R.; Viard, M.; Kireeva, M.L.; Bindewald, E.; Case, C.L.; Maciag, 
A.E.; Kasprzak, W.K.; Kim, T.; Sappe, A.; Stepler, M.; Kewalramani, V.N.; Kashlev, M.; 
Blumenthal, R.; Shapiro, B.A. Nucleic Acids Res. 2014, 42, 2085-2097. 
25 
 
55) Afonin, K.A.; Viard, M.; Martins, A.N.; Lockett, S.J.; Maciag, A.E.; Freed, E.O.; 
Heldman, E.; Jaeger, L.; Blumenthal, R.; Shapiro, B.A. Nat. Nanotechnol. 2013, 8, 296-
304. 
56) Afonin, A.K.; Grabow, W.W.; Walker, M.F.; Bindewald, E.; Dobrovolskaia, A.M.; 
Shapiro, A.B.; Jaeger, L. Nat. Protoc. 2011, 6, 2022-2034. 
57) Ko, S.H.; Su, M.; Zhang, C.; Ribbe, A.E.; Jiang, W.; Mao, C. Nat. Chem. 2010, 2, 1050-
1055. 
58) Endo, M.; Yamamoto, S.; Tatsumi, K.; Emura, T.; Hidaka, K.; Sugiyama, H. Chem. 
Commun. 2013, 49, 2897-2881. 
59) Wang, P.; Ko, S.H.; Tian, C.; Hao, C.; Mao, C. Chem. Commun. 2013, 49, 5462-5464. 
60) Zheng, H.N.; Ma, Y.Z.; Xiao, S.J. Chem. Commun. 2014, 50, 2100-2103. 
61) Afonin, K.A.; Kasprzak, W.K.; Bindewald, E.; Kireeya, M.; Viard, M.; Kashlev, M.: 
Shapiro, B.A. Acc. Chem. Res. 2014, 47, 1731-1741. 
62) Afonin, K.A.; Kireeva, M.; Grabow, W.W.; Kashlev, M.; Jaeger, L.; Shapiro, B.A. Nano 
Lett. 2012, 12, 5192-5195. 
63) Lee, J.B.; Hong, J.; Bonner, D.K.; Poon, Z.; Hammond, P.T. Nat. Mater. 2012, 11, 316-
322. 
64) Afonin, K.A.; Viard, M.; Kagiampakis, I.; Case, C.L.; Dobrovolskaia, M.A.; Hofmann, J.; 
Vrzak, A.; Kireeva, M.; Kasprzak, W.K.; KewalRamani, V.N.; Shapiro, B.A. ACS Nano 
2015, 9, 251-259. 
65) Yu, J.; Liu, Z.; Jiang, W.; Wang, G.; Mao, C. Nat. Commun. 2015, 6, 5724-5729. 
66) Novikova, I.V.; Hassan, B.H.; Mirzoyan, M.G.; Leontis, N.B. Nucleic Acids Res. 2011, 39, 
2903-2917. 
67) Horton, N.C.; Finzel, B.C. J. Mol. Biol. 1996, 264, 521-533. 
68) Geary, C.; Rothemund, P.W.; Andersen, E.S. Science 2014, 345, 799-804. 
69) Seyhan, A.A.; Vlassov, A.V.; Johnston, B.H. Oligonucleotides 2006, 16, 353-363. 
70) Han, D.; Park, Y.; Nam, H.; Lee, J.B. Chem. Commun. 2014, 50, 11665-11667. 
71) Dabkowska, A.P.; Michanek, A.; Jaeger, L.; Rabe, M.; Chworos, A.; Hook, F.; Nylander, 
T.; Sparr, E. Nanoscale 2015, 7, 583-596. 
72) Lander, E.S.; Linton, L.M.; Birren, B.; Nusbau, C.; Zody, M.C.; Baldwin, J.; Davon, K.; 
Dewar, K. et al. Nature 2001, 409, 860-921. 
73) Sailor, M.J.; Park, J.H. Adv. Mater. 2012, 24, 3779-3802. 
74) Gao, Y.; Liu, X.L.; Li, X.R. J. Nanomedicine 2011, 6, 1017-1025. 
75) Gao, J.; Yu, Y.; Zhang, Y.; Song, J.; Chen, H.; Li, W.; Qian, W.; Deng, L.; Kou, G.; Chen, 
J.; Guo, Y. Biomaterials 2012, 33, 270-282. 
76) Zeng, X.; Pan, S.; Li, J.; Wang, C.; Wen, Y,; Wu, H.; Wang, C.; Wu, C.; Feng, M. 
Nanotechnology 2011, 33, 375102. 
77) Kam, N.W.; Liu, Z.; Dai, H. J. Am. Chem. Soc. 2005, 127, 12492-12493. 
78) Bonner, D.K.; Leung, C.; Chen-Liang, J.; Chingozha, L.; Langer, R.; Hammond, P.T. 
Bioconjug. Chem. 2011, 22, 1519-1525. 
79) Lytton-Jean, A.K.; Langer, R.; Anderson, D.G. Small 2011, 7, 1932-1937. 
80) Grabow, W.W,; Jaeger, L.  Acc. Chem. Res. 2014, 47, 1871-1880.  
81) Guo, P.; Haque, F.; Hallahan, B.; Reif, R.; Li, H. Nucleic Acid Ther. 2012, 22, 226-245. 
26 
 
82) Shu, D.; Shu, Y.; Haque, F.; Abdelmawla, S.; Guo, P. Nat. Nanotechnol. 2011, 6, 658-667. 
83) Abdelmawla, S.; Guo, S.; Zhang, L.; Pulukuri, S.; Patankar, P.; Conley, P.; Trebley, J.; 
Guo, P.; Li, Q.X. Mol. Ther. 2011, 19, 1312-1322. 
84) Shu, Y.; Haque, F.; Shu, D.; Li, W.; Zhu, Z.; Kotb, M.; Lyubchenko, Y.; Guo, P. RNA 
2013, 19, 766-777. 
85) Fire, A.; Xu, S.Q.; Montgomery, M.K.; Kostas, S.A.; Driver, S.E.; Mello, C.C.  Nature 
1998, 391, 806-811. 
86) Davis, M.E.; Zuckerman, J.E.; Choi, C.H.; Seligson, D.; Tolcher, A.; Alabi, C.A.; Yen, Y.; 
Heidel, J.D.; Ribas, A. Nature 2010, 464, 1067-1070. 
87) Sen, GL.; Blau, H. M. FASEB J. 2006, 20, 1293-1299. 
88) Dogini, D.B.; Pascoal, V.D.; Avansini, S.H.; Vieira, A.S.; Pereira, T.C.; Lopes-Cendes, I. 
Genet. Mol. Biol. 2014, 37, 285-293. 
89) Castonotto, D.; Rossi, J.J. Nature 2009, 457, 426-433. 
90) Patil, V.S. Zhou, R., Rana, T.M. Biochem. Mol. Biol. 2014, 49, 16-32. 
91) Resnier, P.; Montier, T.; Mathieu, V.; Benoit, J.P.; Passirani, C. Biomaterials 2013, 34, 
6429-6443. 
92) Shu, D.; Shu, Y.; Haque, F.; Abdelmawla, S.; Guo, P. Nat. Nanotechnol. 2011, 6, 658-667. 
93) Haque, F.; Shu, D.; Shu, Y.; Shlyakhtenko, L.; Rychahou, P.; Evers, M.; Guo, P. Nano 
Today 2012, 7, 245-257. 
94) Lee, H.; Lytton-Jean, A.K.; Chen, Y.; Love, K.T.; Park, A.I.; Karagiannis, E.D.; Sehgal, 
A.; Querbes, W.; Zurenko, C.S.; Jayaraman, M.; Peng, C.G.; Charisse, K.; Borodonysky, 
A.; Manoharan, M.; Donahoe, J.S.; Truelove, J.; Nahrendorf, M.; Langer, R.; Anderson, D. 
G. Nat. Nanotechnol 2012, 7, 389-393. 
95) Maina, A.; Blackman, B.A.; Parronchi, C.J.; Morozko, E.; Bender, M.E.; Blake, A.D.; 
Sabatino, D. Bioorg. Med. Chem. Lett. 2013, 23, 5270-5274. 
96) Chang, C.I.; Lee, T.Y.; Kim, S.; Sun, X.; Hong, S.W.; Yoo, J.W.; Dua, P.; Kang, H.S.; 
Kim, S.; Li, C.J.; Lee, D.K. J. Gene Med. 2012, 14, 138-146. 
97) Nakashima, Y.; Abe, H.; Abe, N.; Aikawa, K.; Ito, Y. Chem. Commun. 2011, 47, 8367-
8369. 
98) Hong, C.A.; Eltoukhy, A.A.; Lee, H.; Langer, R.; Anderson, D.G.; Nam, Y.S. Angew. 
Chem. Int. Ed. Engl. 2015, 54, 6740-6744. 
99) Li, Y.; Tseng, Y.D.; Kwon, S.Y.; D’Espaux, L.; Bunch, J.S.; McEuen, P.L.; Luo, D. Nat. 
Mater. 2004, 3, 38-42. 
100) Abe, N.; Abe, H.; Ito, Y. J. Am. Chem. Soc. 2007, 129, 15108-15109. 
101) Abe, N.; Abe, H.; Ohshiro, T.; Nakashima, Y.; Maeda, M.; Ito, Y. Chem. Commun. 
(Camb). 2011, 47, 2125-2127. 
102) Abe, N.; Abe, H.; Nagai, C.; Harada, M.; Hatakeyama, H.; Harashima, H.; Ohshiro, T.; 
Nishihama, M.; Furukawa, K.; Maeda, M.; Tsuneda, S.; Ito, Y. Bioconjug. Chem. 2011, 22, 
2082-2090. 
103) Kim, H.; Park, Y.; Lee, J. Sci. Rep. 2015, 5, 12737. 
104) Kim, H.; Lee, J.S.; Lee, J.B. Sci. Rep. 2016, 6, 25146. 
105) Resnier, P.; Montier, T.; Mathieu, V.; Benoit, J.P.; Passirani, C. Biomaterials 2013, 34, 
6429-6443. 
27 
 
106) Uchino, K.; Ochiya, T.; Takeshita, F. Jpn. J. Clin. Oncol. 2013, 43, 596-607. 
107) Iyer, A.K.; Khaled, G.; Fang, J.; Maeda, H. Drug Discov. Today 2006, 11, 812-818. 
108) Greish, K.J. Drug Target 2007, 15, 457-564. 
109) Wu, J.; Huang, W.; He, Z. ScientificWorldJournal 2013, 2013, 630-654. 
110) Lee, S.E.; Sasaki, D.Y.; Perroud, T.D.; Yoo, D.;  Patel, K.D.; Lee, L.P. J. Am. Chem. Soc. 
2009, 131, 14066-14074. 
111) Landen, C.N. Jr.; Chavez-Reyes, A.; Bucana, C.; Schmandt, R.; Deavers, M.T.; Lopez-
Berestein, G.; Sood, A.K. Cancer Res. 2005, 65, 6910-6918. 
112) Lee, J.M.; Yoo, T.J. Cho, Y.S. Biomed. Res. Int. 2013, 782041. 
113) Hong, C.A.; Nam, Y.S. Theranostics, 2014, 4, 1211-1232.  
114) Hsiang, T.; Zhao, C.; Krug, M.R. J. Virol. 2009, 83, 5971-5977. 
115) Singha, K.; Namgung, R.; Kim, W.J. Nucleic Ther. 2011, 21, 133-147. 
116) Yin, H.; Kanasty, R.L.; Eltoukhy, A.A.; Vegas, A.J.; Dorkin, J.R.; Anderson, D.G. Nat. 
Rev. Genet. 2014, 15, 541-555. 
117) Adjei, I.; Sharma, B.; Labhasetwar, V. Adv. Exp. Med. Biol. 2014, 811, 73-91. 
118) Ardana, A.J. Chem. Technol. Biotechnol. 2015, 90, 1196-1208. 
119) Kim, T.; Hyeon, T. Nanotechnology 2014, 25, 012001. 
120) Huang, C.; Zhang, Y.; Yuan, H.; Gao, H.; Zhang, S. Nano Lett. 2013, 13, 4546-4550. 
121) Li, X. J. Appl. Phys. 2012, 111, 024702. 
122) Murugan, K.; Choonara, Y.E.; Kumar, P.; Bijukumar, D.; du Toil, L.C.; Pillay, V. Int. J. 
Nanomedicine 2015, 10, 2191-2206. 
123) Chithrani, B.D.; Ghazani, A.A.; Chan, W.C. Nano Lett. 2006, 6, 662-668. 
124) Toy, R.; Peiris, P.M.; Ghaghada, K.B.; Karathanasis, E. Nanomedicine (Lond) 2014, 9, 
121-134. 
125) Prabha, S.; Zhou, W.Z.; Panyam, J.; Labhaswtwar, V. Int. J. Pharm. 2002, 5, 105-115. 
126) Nam, H.Y.; Kwon, S.M.; Chung, H.; Lee, S.Y.; Jeon, H.; Kim, Y.; Park, J.H.; Kim, J.; Her, 
S.; Oh, Y.K.; Kwon, I.C.; Kim, K.; Jeong, S.Y. J. Control. Release 2009, 135, 259-267. 
127) Danhier, F.; Feron, O.; Preat, V. J. Control. Release 2010, 148, 135-146. 
128) Beddoes, C.M.; Case, C.P.; Briscoe, W.H. Adv. Colloid. Interface Sci. 2015, 218, 48-68. 
129) Ho, C.C.; Ding, S.J. J. Mater. Sci. Mater. Med. 2013, 24, 2381-2390. 
130) Whitehead, K.A.; Langer, R.; Anderson, D.G. Nat. Rev. Drug Discov. 2009, 8, 129-138. 
131) Katas, H.; Alpar, H.O. J. Control Release 2006, 115, 216-225. 
132) Deleavery, G.F.; Damha, M. J. Chem. Biol. 2012, 19, 937-954. 
133) Wang, A.Z.; Langer, R.; Farokhzad, O.C. Annu. Rev. Med. 2012, 63, 185-198. 
134) Jeong, J.H.; Mok, H.; Oh, Y.K. Bioconjug. Chem. 2008, 20, 5-14. 
135) Chiu, Y.L.; Ali, A.; Chu, C.Y.; Cao, H.; Rana, T.M. Chem. Biol. 2004, 11, 1165-1175. 
136) Moschos, S.A.; Jones, S.W.; Perry, M.M.; Williams, A.E.; Erjefalt, J.S.; Turner, J.J.; 
Barnes, P.J.; Sproat, B.S.; Gait, M.J.; Lindsay, M.A. Bioconjug. Chem. 2007, 18, 1450-
1459. 
137) Cesarone, G.; Edupuganti, O.P.; Wickstrom, E. Bioconjug. Chem. 2007, 18, 1831-1840. 
138) Xu, W.; Pan, R.; Zhao, D.; Chu, D.; Wu, Y.; Wang, R.; Chen, B.; Ding, Y.; Sadatmousavi, 
P.; Yuan, Y.; Chen, P. Mol. Pharm. 2015, 12, 56-65. 
139) Chu, T.C.; Twu, K.Y.; Ellington, A.D.; Levy, M. Nucleic Acids Res. 2006, 34, 73. 
28 
 
140) Toloue, M.M.; Ford, L.P. Methods Mol. Biol. 2011, 764, 123-39. 
141) Lee, K.; Oh, M.H.; Lee, M.S.; Nam, Y.S.; Park, T.G.; Jeong, J.H. Int. J. Pharm. 2013, 445, 
196-202. 
142) Li, S.D.; Huang, L. Curr. Opin. Investig. Drugs 2008, 9, 1317-1323. 
143) Bolcato-Bellemin, A.L.; Bonnet, M.E.; Creusat, G.; Erbacher, P.; Behr, J.P. Proc. Natl. 
Acad. Sci. USA 2007, 104, 16050-16055. 
144) Liu, X.; Liu, C.; Laurini, E.; Posocco, P.; Pricl, S.; Qu, F. Mol. Pharm. 2012, 9, 470-481. 
145) Mok, H.; Lee, S.H.; Park, J.W.; Park, T.G. Nat. Mater. 2010, 9, 272-278. 
146) Lee, S.Y.; Huh, M.S.; Lee, S.; Lee, S.J.; Chang, H.; Park, J.H. J. Control Release 2010, 
141, 339-346. 
147) Lee, S.Y.; Mok, H.; Jo, S.; Hong, C.A.; Park, T.G. Biomaterials 2011, 32, 2359-2368. 
148) Chung, H.J.; Hong, C.A.; Lee, S.H.; Jo, S.D.; Park, T.G. Bioconjug. Chem. 2011, 22, 299-
306. 
149) Jo, S.D.; Kim, J.S.; Joie, C.O.; Mok, H.; Nam, Y.S. Macromol. Biosci. 2014, 14, 195-201. 
150) Kong, W.H.; Bae, K.H.; Hong, C.A.; Lee, Y.; Hahn, S.K.; Park, T.G. Bioconjug. Chem. 
2011, 22, 1962-1969. 
151) Hong, C.A. Lee, S.H.; Kim, J.S.; Park, J.W.; Bae, K.H.; Mok, H. J. Am. Chem. Soc. 2011, 
133, 13914-13917. 
152) Young, S.W.; Stenzel, M.; Yang, J.L. Crit. Rev. Oncol. Hematol. 2016, 98, 159-169. 
153) Mansoori, B.; Shotorbani, S.S.; Baradaran, B. Adv. Pharm. Bull. 2014, 4, 313-321. 
154) Forsbach, A.; Muller, C.; Montino, C.; Kritzler, A.; Curdt, R.; Benahmed, A.; Jurk, M.; 
Vollmer, J. Immunol. Lett. 2012, 141, 169-180. 
155) Mikkola, S.; Kosonen, I.; Lonnberg, H. Curr. Org. Chem. 2002, 6, 523-538. 
156) Lundy, B.B.; Convertine, A.; Miteva, M.; Stayton, S.P. Bioconjug. Chem. 2013, 24, 398-
407. 
 
 
 
 
 
 
 
 
29 
 
CHAPTER 2: HYBRIDIZATION AND SELF-ASSEMBLY OF RNA 
INTO STABLE THREE COMPONENT SYSTEMS (3CS) 
2.1 Abstract 
In this chapter, the prerequisite conditions for forming stable hybrid RNA assemblies are 
described. The study involved the design of linear RNA template sequences and two 
complementary strands with base-pairing fidelity that facilitated higher-order self-assembly into 
stable three-component RNA systems. Solid phase RNA synthesis was performed in order to 
obtain the crude RNA sequences. All synthesized RNA sequences were then purified by RP-IP-
HPLC and characterized by mass spectrometry. In order to optimize the conditions for self-
assembly of the stable RNA hybrid three component system (3CS), parameters such as RNA 
sequence length, buffer conditions and salt concentration were screened for hybridization. The 
influence of the hybridization conditions on RNA self-assembly of the 3CS were analyzed by 
native polyacrylamide gel electrophoresis (PAGE), which distinguished hybrid vs non-hybrid 
RNA based on their differences in electrophoretic mobilities on the gel. Furthermore, the thermal 
stabilities (Tm) of the RNA hybrid 3CSs were evaluated by thermal denaturation which indicated 
the most stable hybrid conditions with the highest Tm values. The RNA hybrids were also found to 
form the canonical A-type helical hybrid structure in various buffer conditions as examined by 
circular dichroism (CD) spectroscopy. These characterization studies revealed that the 30 
nucleotide (nt) long RNA template strand, RNAT30, was required to self-assemble the two 
complementary RNA strands of 15 nt, RNAC15 and 23 nt, RNAC23   to form the stable RNA 3CS. 
Moreover, the self-assembled RNA 3CS was stably formed using Tris buffer, which supported the 
stabilizing effects of the salts present in the buffer. 
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2.2 INTRODUCTION 
2.2.1 Solid Phase RNA Synthesis 
  Many synthetic strategies have been developed to generate biologically active RNAs for 
applications in biology, chemical biology, and medicine in addition to the advancement of bio-
technologies. The synthesis of RNA has always been a challenge due to its many reactive 
functional groups and higher-order structures. Since the 1950s two widely developed strategies 
have been implemented: 1) Enzymatic synthesis and 2) Chemical synthesis, each method has 
gained in popularity with the rise of technological innovations in the field.1,2,3 In this thesis, I will 
discuss the automated solid phase synthesis of RNA and underscore its benefits for producing a 
wide range of RNAs for the many applications that have evolved from chemical synthesis 
procedures. Solid phase RNA synthesis enables the incorporation of native or modified RNA 
monomers for making RNA oligonucleotides in sufficient quantities for biological and therapeutic 
applications.4,5 The automated synthesis of RNA begins with the selection of the solid support. The 
solid support is preferably insoluble in organic or aqueous solvents and chemically inert 
throughout of the entire RNA synthesis cycle.6,7 A variety of compatible polymeric materials have 
been designed and developed for RNA synthesis. These include: Divinylbenzene cross-linked 
Polystyrene6 (DVB-PS), Macroporous8 Polystyrene (MPPS) or Controlled Pore Glass7 (CPG). 
Among the different types of solid supports that have been produced, CPG has been widely 
accepted for both small to commercial production levels of RNA. The CPG is commercially 
available with different pore sizes ranging from 500-3000 Å, with the larger pore sizes respectively 
facilitating the growth of lengthy and larger RNA sequences and structures.7 Linkers have been 
functionalized onto the CPG for the efficient growth and isolation of RNA from the solid support.  
For example, the long chain alkyl amine linker such as the succinyl linker9a, hydroquinone-O-O’-
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diacetic acid derived Q- or HDQA-linker,11 the photo- labile linker such as the ortho-nitrobenzyl 
linker12 and the universal linkers 9,10 that allow the rapid and efficient synthesis of a wide range of 
RNA sequences. The first RNA monomers attached to the succinyl linkers on CPG are the most 
routinely used for RNA synthesis. The succinyl-linked CPG support contains the 3’-RNA 
monomer composed with the 5’-dimethoxytrityl (5’-ODMT) 2’-tert-butyldimethylsilyl (2’-
OTBDMS) protecting groups (Figure 2.1). The 5’-ODMT group is acid labile with 3% 
trichloroacetic acid (TCA) or dicholoroacetic acid (DCA) in dichloromethane (DCM) and can be 
monitored during deprotection by trityl cation color analyses using UV-Vis spectroscopy. The 
loading capacity (mol of RNA/ g of solid support) determines the stoichiometric quantity of RNA 
monomers attached to the solid support. It is used for calculating synthesis yields and efficiencies. 
The higher loading supports (i.e. 80-100 µmol/g) enable the production of greater RNA amounts 
and is especially useful in bulk RNA synthesis at lower costs.13 Each chemical step is optimized 
to completion by introducing an excess of reagents to the column containing CPG, while 
facilitating RNA synthesis on solid support. Moreover, the solid phase synthesis procedure 
alleviates the need for step-wise work-up and purification steps. Following each reaction step, 
excess reagents are filtered through the column and into the waste container. Following RNA 
synthesis, a final post-synthesis cleavage and deprotection procedure is used to isolate the crude 
RNA from the solid support. The crude RNA is quantitated by UV-Vis spectroscopy, analyzed 
and purified by HPLC and finally characterized by MS which validates sequence identity based 
on molecular weight.   
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Figure 2.1 Control pore glass (CPG) attached with (1) amino succinyl universal linker and (2) 
the first 5-ODMT 2’-OTBDMS RNA nucleotide (Base: AN-Bz,GN-Ac,CN-Ac,U) attached to the 
succinyl linker CPG support. 
 
 
2.2.2 RNA PHOSPHORAMIDITES FOR SOLID PHASE RNA SYNTHESIS 
The conventional RNA building blocks for automated RNA solid phase synthesis contain 
three  types of protecting groups: 1) 5’-OH acid labile protecting groups (DMT or MMT), 2) 2’-
OH  fluoride labile protecting groups (-OTBDMS), 3) exocyclic –NH2 base labile protecting 
groups on bases (N-Bz, N-Ac, N-iBu) and a 3’-phosphoramidite facilitating coupling to the nascent 
support-bound RNA (Figure 2.2). Even though these RNA building blocks are commonly used in 
RNA synthesis, their application in lengthy RNA syntheses (> 50 nt) is limited due to the steric 
influence imparted by the bulky 2’-OTBDMS protecting groups. For the efficient synthesis of 
lengthy RNA sequences, a number of new 2’-protecting groups have been developed.14 For 
example, the chemical synthesis of the 43 nt long RNA corresponding to the 3’-terminus of a 
formylmethionine tRNA of Escherichia coli on CPG solid support using 2’-OTBDMS protecting 
group has been carried out.17 Another 110 nt long precursor-microRNA was synthesized using 2-
cyanoethoxymethyl (CEM) as a 2’-O-protecting group by solid phase RNA synthesis.15 
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Figure 2.2 Commercially available RNA phosphoramidites with their protecting groups for solid 
phase RNA synthesis (RNA phosphoramidites commercially available at Chemgenes Inc. 
Wilmington, MA). 
 
 
 
 
 
 
34 
 
2.2.3 Automated Solid Phase RNA Synthesis, Cleavage and Deprotection from the Solid Support 
 The discovery of the automated RNA solid phase synthesis cycle has facilitated the small 
(microgram to milligram), and bulk (gram to kilogram) scale production of native and modified 
synthetic RNAs using various phosphoramidite RNA building blocks.17   
 
Scheme 2.1 Automated solid phase RNA synthesis cycle. Figure has been adapted from ref 16: 
Iyer, R.P.; Kuchimanchi, S.N.; Panday, R.K. Drugs Fut. 2003, 28, 51. 
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The automated solid phase RNA synthesis cycle (Scheme 2.1) allows the rapid growth of 
RNA on solid support from the 3’- to 5’-end of the target sequence. During the synthesis cycle, 
the very first detritylation step of the 5’-DMT group is conducted by delivering into the synthesizer 
column containing the CPG a solution of 3% DCA:DCM  for 90 seconds to ensure complete 
detritylation. In the subsequent step, the CPG is washed with DCM to remove any residual DMT+. 
In the following coupling step, the pre-dissolved RNA phosphoramidites (0.15 M) in anhydrous 
acetonitrile (MeCN), are mixed with the coupling reagent, 0.25 M 5-ethylthiotetrazole (ETT), in 
MeCN for activation and coupling to the RNA bound CPG solid support. Typically, the coupling 
reaction takes places in 6-10 minutes but coupling times can be varied based on the composition 
of the RNA phosphoramidites (e.g. riboguanosine requires 15 minute couplings due to the bulky 
N-iBu and 2’-TBDMS protecting groups) or to enhance coupling efficiencies of modified 
phorphoramidites (e.g. branchpoint ribouridine phosphoramidite).18 After the coupling step, the 
RNA bound CPG is washed with MeCN and any uncoupled RNA is capped. The capping step is 
of prime importance to prevent the elongation of uncoupled RNA failure sequences (i.e. n-1, n-2, 
n-3……. etc.). In this step any uncoupled RNA is capped with the capping reagents (Cap A: 1:1:8 
v/v/v acetic anhydride:pyridine:tetrahydrofuran, Cap B: 16% N-methyl imidazole in 
tetrahydrofuran) for 12-15 seconds. If incomplete capping is anticipated in difficult to couple 
sequences, two capping cycles may be applied to ensure 100% capping efficiency (e.g V-shape 
and Y-shape siRNA synthesis).18 In this study, the RNA coupling steps were optimized to 96-98% 
coupling efficiency thereby minimizing the accumulation of failure sequences. Following capping, 
oxidation of the RNA backbone from the more reactive phosphite to the more stable phosphate 
triester19 is accomplished using 0.02 M oxidant (I2 in 75/20/5 v/v/v 
tetrahydrofuran/pyridine/water) for 14 seconds. This step is also essential because the trivalent 
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phosphite triester group is reactive and can lead to 3’- to 2’- isomerization and cleavage of the 
RNA strand under neutral, acidic and basic conditions.20 The RNA bound support is then washed 
with MeCN and dried with argon prior to 5’-detritylation of the last attached RNA monomer. The 
synthesis cycle continues until the desired sequence has been completed.  
 Once the desired RNA sequence is synthesized, the RNA linked CPG is subjected to 
cleavage (removal of the RNA from the solid support) and deprotection (removal of the exocyclic 
nucleobase protecting groups and the cyanoethyl groups from the phosphate triester backbone) 
using alkaline conditions. Typically, a 1:1 v/v ammonium hydroxide: methylamine (1:1 AMA) 
solution is applied for 10 min at 65 ºC for the cleavage and deprotection step of RNA containing 
labile nucleobase protecting groups (e.g. N-Bz, N-Ac). However, harsher conditions are applied 
when the RNA base protecting groups (e.g. Guanine base, N-iBu) are more resilient to the AMA 
conditions. These conditions use a 3:1 v/v ammonium hydroxide in ethanol (3:1 v/v 
NH4OH:EtOH) solution for 14 -18 hours at 55 ºC. The alkaline solution is volatile and can be then 
evaporated on a Speedvac® concentrator. The dried, crude RNA is then recovered from the CPG 
by extraction with sterile, autoclaved distilled water and evaporated to obtain the dried crude RNA 
pellet. The crude RNA is then treated with a 1:1 v/v dimethylsufoxide:trimethylamine 
trihydrofluoride (1:1 DMSO:TEA.3HF, 125 µL each) solution at 65 ºC for 2 hours to remove the 
2’-OTBDMS protecting group. In the very last step, the crude RNA is precipitated with 3 M 
NaOAc (30 µL) in n-BuOH (1 mL), isolated by centrifugation and redissolved in autocleaved 
distilled water for further quantitative analysis by UV-Vis Spectroscopy.  Crude RNA analysis and 
purification is next accomplished by IP-RP-HPLC27 and/or polyacrylamide gel electrophoresis.21 
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2.2.4 Qualitative Analysis and Purification of RNA by IP-RP-HPLC 
Many techniques are currently available for the isolation, purification and quantification of 
RNA. The crude qualitative analysis of RNA is commonly accomplished by ion-pair reverse-phase 
high performance liquid chromatography (IP-RP-HPLC).25 This method is especially useful for 
the analyses of double-stranded RNA under non-denaturing conditions, and single-stranded RNA 
using partially and completely denaturing conditions by varying salt concentrations and buffer pH. 
The denaturing HPLC conditions have gained widespread acceptance for RNA analysis and 
purification.22-25  
In IP-RP-HPLC, the RP column contains a non-polar stationary phase, typically C-18 
(although C-8 columns have been used) derivitized silica with different particle sizes.26-29 The 
particle sizes of 8-30 m have been most commonly used for the separation of lengthier, more 
hydrophobic RNA sequences that have greater retention and separation on the RP column.30 The 
buffer conditions also play a critical role in IP-RP-HPLC. A commonly used ion pairing buffer for 
RNA analysis is composed of the alkyl ammonium salts (eg. TEAA) formed from the acid/base 
reaction in between acetic acid (AA) and triethylamine (TEA). The buffer is maintained near 
neutral pH and serves a very important function in stabilizing the hydrophobic interactions in 
between the eluting RNA in the mobile phase and the stationary phase. Also, the use of organic 
solvents such as acetonitrile (MeCN) is combined with the TEAA buffer in the mobile phase to 
facilitate RNA elution and the washing of non-polar synthetic RNA impurities, such as those 
accumulated from incomplete deprotection of the bulky, hydrophobic protecting groups. Figure 
2.3 shows a typical IP-RP-HPLC chromatogram with increased resolution in between the desired 
RNA target sequence and the n-1 failure sequences which are typically shorter, more hydrophilic 
and faster eluting with shorter retention times. The lengthier (n+1) RNA sequences as a result of 
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the incorporation of additional RNA monomer units or due to incomplete deprotection will lead to 
more  hydrophobic RNA sequences that elute slower with longer retention times. The n-1 and n+1 
sequences are typically difficult to separate from the target RNA sequence, therefore, careful 
optimization of the gradient elution system is necessary in order to obtain pure RNA product.28 
Moreover, the crude RNA may also be susceptible to self-folding into higher-order secondary 
structures which makes the analysis and purification more difficult to accomplish. In these 
instances, denaturing conditions may be applied by increasing the column temperatures to 50-70 
ºC which causes the denaturation of any high-order structures and clean analyses of the native 
RNA primary sequence. The RNA analysis on HPLC is monitored by the UV absorbance at 260 
nm.28,29 Following analysis and purification of the crude RNA, the volatile eluent components can 
be evaporated on a Speed Vac concentrator, leaving behind the pure RNA pellet that can be further 
characterized by a combination of gel electrophoresis, mass spectrometry and UV-Vis, CD 
spectroscopy.  
 
 
 
 
 
 
 
Figure 2.3 A typical IP-RP-HPLC chromatogram of a crude RNA sequence.     
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2.2.5 Qualitative Analysis of RNA by Polyacrylamide Gel Electrophoresis (PAGE) 
The polyacrylamide gel electrophoresis (PAGE) technique is a useful analytical technique 
to assess RNA purity (under denaturing conditions) and for the characterization of self-assembled 
hybrid structures (under native conditions).32-35 The separation of crude RNA under denaturing 
PAGE conditions requires the preparation of the RNA sample in 0.1% formamide in TBE buffer 
and with a PAGE gel containing urea. These conditions separate crude RNA samples based on 
RNA sequence composition, size, shape and charge differences. The RNA migrates through pores 
of the gel with an applied electric current, with the smaller sequences (<18 nucleotides) migrating 
faster while the lengthier sequences (>30 nucleotides) migrate slower and with shorter 
electrophoretic mobilities on the gel, Figure 2.4.31 Native PAGE analysis can be useful in 
characterizing hybrid RNA structures in a non-denaturing sucrose-TBE buffer and with a PAGE 
gel prepared without urea. Moreover, the amount of polyacrylamide varies from preparation to 
preparation and typically accounts for 18-25 nt long RNA, as a 20-24% PAGE and for RNA >45 
nt, as a 10-18% PAGE solution. Under these conditions, native PAGE analyses has been used to 
track hybrid RNA,36 ligand-RNA37 and peptide/protein-RNA38 complex formation. Following 
RNA PAGE analysis, the gel can be visualized under a UV light (260 nm absorbance) or with an 
intercalating dye solution (such as ethidium bromide) which displays the RNA as purple colored 
bands, Figure 2.4.  
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Figure 2.4 Polyacrylamide gel electrophoresis of RNA:RNA hybrids under UV shadow and after 
staining with ethidium bromide. 
 
2.2.6 Mass Spectrometry Analysis of RNA 
Mass spectrometry (MS) is a very sensitive RNA analysis technique due to its ability to 
provide molecular weight and sequence information of a limited amount of sample.39,40 The 
analysis of RNA by mass spectrometry is based on sample ionization with an ion source under 
high pressure and temperature conditions, followed by mass ion separation and fragmentation 
within the mass analyzer leading to the detection of ions as mass to charge ratios. The computer 
aided software algorithms enable interpretation of RNA fragment ion data by providing mass to 
charge ratios (m/z). Sample ionization for RNA is typically accomplished by electron spray 
ionization (ESI).41 This ESI ion source is coupled with a triple quadrupole or time of flight mass 
analyzer which facilitates high resolution mass spectra (HRMS) data collection. This provides 
exact molecular weight identification of RNA in addition to mass ion fragmentation patterns 
collected from MS/MS methods that are designed to provide information on the sequence 
composition. The latter has been applied to the sequencing of biological RNA and entire RNA 
genomes.42 Matrix-assisted laser desorption/ionization of time flight mass spectroscopy (MALDI-
TOF-MS) has also been used as an analytical approach for obtaining mass information of RNAs.43 
MALDI-TOF MS requires the RNA sample to be embedded within a suitable matrix, typically 
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composed of aza-thiothymine/spermine and L-fucose, which is then subjected to a UV laser beam 
causing sample absorption, followed by desorption from the matrix and ionization. The ions 
generated are then separated and detected by the TOF-MS producing a mass spectrum of the RNA 
sample in positive (protonated) or negative (deprotonated) mode. 
In ESI mass spectrometry the parent ions are typically not observed. Rather, multiple 
negatively charged species are detected in the mass spectrum and deconvoluted to provide mass 
sequence identity. The ESI method provides better mass accuracy, resolution, and sensitivity for 
lengthy RNAs (from 20-120 base-pairs) while MALDI-TOF analysis has been used to characterize 
very large, genomic RNA sequences.44 Moreover, RNA mass analysis may also be accomplished 
by coupling mass spectrometry with HPLC, for in-line chromatographic separation and mass 
characterization.45 Thus, LC-MS provides a nice instrumental technique for rapidly separating 
RNA sequences and characterizing their composition.  
2.2.7 UV-Vis Spectroscopy Analysis of RNA Thermal Denaturation  
Thermal denaturation analysis is commonly used to assess RNA hybrid stability. The 
experiment uses a UV-VIS spectrophotometer to measure the changes in absorption of the RNA 
bases in the hybrid vs. non-hybrid form. In this assay, the RNA nucleobases will exhibit greater 
changes in UV absorption with increasing temperatures (% hyperchromicity) as the RNA hybrid 
denatures into separate, single-stranded sequences (Figure 2.5). The nucleobases within the RNA 
sequences have absorptivities in the far-UV (210-310 nm) region. Thus, any change in RNA 
secondary structure can be effectively quantitated at 260 nm (A260). The typical UV absorption at 
260 nm increases when the RNA hybrid duplex transitions to random, single-stranded RNA 
sequences. In the denatured single-stranded form, RNA owns the ability to absorb light more 
strongly relative to the hybrid duplex form. The stable WC hydrogen bonding interactions in 
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between the hybrid RNA strands can be disrupted by denaturing agents such as formamide, urea 
and heat. Therefore, thermal denaturation provides a measure of RNA thermal stability by 
monitoring the % changes in hyperchromicities at 260 nm with increasing temperatures. The 
experiment yields a phase transition (helix-coil transition) or denaturation curve signaling the 
transition of an RNA hybrid duplex to single stranded form. The midpoint of this curve provides 
the melting temperature (Tm ºC) at which 50% of the RNA duplex has denatured to single-stranded 
form. The higher the melting temperature the more stable the RNA hybrid structures (Figure 2.5). 
 
Figure 2.5 A typical melting curve of a hybrid RNA duplex. 
Melting experiments have been used to determine the thermal stabilities of homopurine-
homopyrimidine oligonucleotide duplexes. In these experiments, RNA hybrids were found to be 
more stable when compared to DNA or DNA:RNA hybrids[(rPu)(rPy) > (rPu)(dPy) > (dPu)(dPy) 
> (dPu)(rPy)].46 The inherent stabilities of RNA hybrids has been related to their conformational 
properties, in which the more compact C3’-endo RNA conformation contributes to a tighter, more 
stable hybrid assembly.47 Thus, RNA may function as a stable template for the self-assembly of 
higher-order RNA structures.   
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2.2.8 CD spectroscopy analysis of RNA 
The chiral, optical activity of RNA is results from its ability to absorb and rotate circularly 
polarized light in the far-UV region (200-300 nm). The frequency dependent differences in the 
absorption of circularly polarized light provides a circular dichroism (CD) signal indicative of the 
RNA secondary structure in solution. The CD spectra of duplex RNA hybrids are indicative of an 
A-type RNA helical trajectory (Figure 2.6). A typical A-type RNA CD spectra features a positive 
maximum band near 260 nm and negative minima near 210 nm and also in between 235-250 nm.48 
The amplitude of the positive band is usually within 7-12 M-1 cm-1 depending on the base sequence. 
Another important characteristic of the CD spectra of the A-type RNA hybrids is the peak intensity 
in between 235-250 nm is present as a larger minimum when compared to the peak intensity at 
210 nm; whereas the maximum positive band at 260 nm is typically broad and intense. 
 
Figure 2.6. Structure of the A-type RNA hybrid duplex and the corresponding CD spectrum. 
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2.3 PROJECT OBJECTIVES 
Inspired by the widespread biological function of self-assembled RNA hybrids, this chapter 
examines the requirements for efficient RNA hybridization and self-assembly. This study is 
important for the design and selection of complementary RNAs and the buffer conditions that can 
facilitate efficient hybridization and self-assembly into 3CS. The 3CS RNA structure is composed 
of a linear template strand with base-pairing fidelity which guides the self-assembly with two 
complementary RNA sequences (Figure 2.7). The 3CS is anticipated to be tightly held together in 
favorable buffer conditions. In order to evaluate this hypothesis, solid-phase RNA synthesis, 
purification, hybridization and stability studies of the RNA hybrids are reported in this chapter. 
The hybridization capabilities of the 3CS was evaluated in different buffering conditions in order 
to analyze the effect of the buffer on RNA hybrid stability. The RNA 3CS were characterized by 
PAGE analysis in order to determine the hybridization capabilities. UV-thermal denaturation 
analysis validated the hybrid stabilities in the various buffer systems. Meanwhile, CD spectroscopy 
provided insights on the influence of sequence composition and buffer on RNA secondary 
structure. At the end of this study, optimized conditions for stable RNA hybrid formation are 
described for the efficient self-assembly of RNA hybrids that may have useful applications as RNA 
nanomedicines (Chapter 3). 
 
 
 
 
 
45 
 
2.4 CRITERIA FOR STABLE RNA HYBRIDIZATION AND SELF-ASSEMBLY   
A rising interest in the structure and stability of RNA hybrids is in part based on the 
development of regulatory, non-coding RNAs such as siRNA and miRNA that have been 
successfully applied in the gene therapy of infectious and metabolic disorders, including cancer.49  
RNA conformation, primary sequence composition,  and secondary structure each contribute to 
the stability of RNA hybrids. Moreover, external factors such as choice of solvent, sample and salt 
concertation, buffer composition and pH changes each contribute to the self-assembly and 
hybridization potential of RNA. In our design for studying the influence of intrinsic and external 
factors on RNA self-assembly and hybridization, a template RNA was used to pre-organize the 
self-assembly of complementary RNA sequences that led to the formation of stable RNA 3CS 
(Figure 2.7). In order to gain a better understanding of the requirements for the efficient self-
assembly of higher-order RNA 3CS factors such as, 1) sequence composition, 2) secondary 
structure, 3) buffer conditions were explored and optimized to provide the most efficient 
conditions for RNA hybridization and self-assembly.50-54 
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Figure 2.7 Schematic representation of RNA hybrid three component system (3CS).  RNA 
complemtary strands RNAC15 (Blue) and RNAC23 (Red) shown to hybridize with RNA templates 
RNAT15 (Green), RNAT20 (Pink), RNAT30 (Yellow) to form the three component hybrids 1 (3CS 
R1), 2 (3CS R2) and 3 (3CS R3).  
 
The sequence composition of RNA is of prime importance due to its implications in 
secondary and tertiary structure folding.54 In terms of the individual purines and pyrimidine 
nucleobases found within RNA, the absence of the 5’-methyl group in uracil contributes to a small 
decrease in base-pairing free-energy when compared to the base-pairing capabilities of thymine. 
In addition, the greater number of G:C base pairs within the RNA primary sequences has also been 
shown to increase the hybridization stability. This is due to the increase in number of H-bonding 
interactions found within the G:C base pairs (3) when compared to the A:U base pairs (2).55 Long 
RNA sequences are known to fold onto themselves (self-folding) into secondary and tertiary 
structures that are typically associated with proteins (e.g. rRNA, tRNA). RNA self-folding is based 
on Watson-Crick and Hoogsteen base pairing interactions and must be taken into account when 
selecting RNA templates and complementary strands that can participate in efficient cross-pairing 
interactions while minimizing self-folding effects.54  
The RNA conformation of the phosphodiester backbone also plays an important role in the 
hybridization and self-assembly of complementary sequences.55 The secondary structure of double 
stranded RNA typically forms A-type helical structures, due to the pre-organized ribose sugar 
pucker which adopts a Northern or C3’-endo geometry. In this conformation, the C3’ and C5’ 
carbons lie above the median plane defined by C1’-O4’-C4’ such that the C5’-C3’-phosphate 
diester bond distance is reduced to 5.9 Å, resulting in a more compact and thermodynamically 
stable duplex formation, (Figure 2.6).56 
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Many comparative thermodynamic stability studies according to the nearest-neighboring 
effect (based on sequence composition) have been accomplished on RNA:RNA, DNA:DNA, and 
DNA:RNA hybrid systems.51,53,57-59 However, these studies limit the contributing effects of 
external factors, such as salt composition  and concentration, buffer pH changes on stable hybrid 
formation. RNAs are dependent on a variety of cations found in salt buffers, and their 
concentrations influence RNA hybridization and self-assembly. In the presence of high salt 
concentration (1 M NaCl), stable RNA hybrids persist although RNA hybridization and self-
assembly has also been shown to efficiently occur at physiological salt concentrations (100 mM 
NaCl and MgCl2). The monovalent (Na
+, K+) and divalent (Mg2+) cations have profound effects 
on RNA hybrid stability that cannot be ignored.60 In general, the presence of monovalent cations 
enhances thermal stability (Tm) of the hybrid duplex but the divalent cations stabilizes the duplex 
more effectively. These cations are considered to have different binding sites on the 
ribonucleotides; with Na+ coordinating preferentially with the phosphate group and Mg2+ with the 
N7 of purine bases, including those found in the major and minor groove of RNA hybrids.61,62 
Therefore, the base sequence composition and the ionic strength of monovalent and divalent 
cations play an important role in RNA hybrid duplex stability.51 
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2.5. EXPERIMENTAL SECTION 
2.5.1 Solid Phase Synthesis of Linear RNA Sequences 
The RNA sequences synthesized in this study (Table 2.1) were chosen for their assembly 
into the three component hybrid systems (3CS). The automated solid-phase synthesis cycle for 
RNA was accomplished on a nucleoside derivitized controlled pore glass (CPG) support using the 
ABI 3400 automated solid-phase DNA/RNA synthesizer. The first step involved removal of the 
5′-dimethoxytrityl (DMT) group in acidic conditions (i.e. 3% trichloroacetic acid in 
dichloromethane) followed by coupling of the ribonucleoside phosphoramidites in the presence of  
an activating reagent (i.e. ethylthiotetrazole). Any unreacted starting material was capped by an 
acetylation reaction followed by oxidation of the phosphite to the phosphate triester backbone and 
continuation of the synthesis cycle to generate the full length oligonucleotide. Following cleavage 
of the oligonucleotide from the solid-support and deprotection of phosphate and nucleobase 
protecting groups using alkaline conditions (i.e. 3:1 v/v NH4OH:EtOH), crude RNAs were 
subjected to 2′-desilylation reactions in a triethylamine trihydrofluoride/DMSO mixture. 
Deprotected crude RNAs were desalted by precipitation in cold n-butanol, centrifuged down and 
dried after decanting n-butanol. The dried RNA pellets were then dissolved in autoclaved water 
for further analysis. 
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Table 2.1 Characterization data for the RNA sequences synthesized in this study. 
 
Characterization data for sequences synthesized in this study. aSequence composition, bsize of the 
RNA sequence,  c%crude yields were determined by UV-Vis Spectroscopy, d%yield of isolated 
RNA pure product obtained, e%purity determined by reverse-phase ion-pairing HPLC on a 
WATERS Symmetry C-18 reverse phase column (4.6 x 150 mm, 5 m particle size) using gradient 
of 10-95% (20% MeCN in 0.1M TEAA) over 23 minutes. fMolar mass (g/mol) were calculated 
from the oligo-analyzer software provided by IDT (https://www.idtdna.com/calc/analyzer ) and 
the experimental masses (g/mol) were obtain from ESI-MS analyses in negative mode (NOVATIA 
LLC, Newton PA)  
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2.5.2 Purification and Mass Analysis of RNA Sequences 
The crude RNA sequences were analyzed by IP-RP-HPLC to determine crude purities. 
Briefly, HPLC analyses (0.1 OD) and purification (1 OD) were performed on a Waters® 2695 
Alliance Separations Module. Crude RNA templates were dissolved in autoclaved water (1 mL) 
and injected into a Waters® Symmetry C-18 reverse phase column (4.6 x 150 mm, 5 μm particle 
size, 120 Å) heated at 60 ºC. HPLC analyses and purifications were conducted using a gradient of 
5-95% eluent B (20% acetonitrile in 0.1 M triethylammnonium acetate) in eluent A (0.1 M 
triethylammonium acetate) with a HPLC flow rate of 1 mL/min, run times of 26 minutes and with 
absorbance detection at 260 nm using a Waters 2489 UV/Visible detector. Retention times (min.) 
and peak areas (% area) were integrated with Empower II (Waters®) and used to confirm RNA 
purities ≥96% following sample purifications. Following purification, RNA sequences (0.1-0.4 
μM) were dissolved in Millipore water (1 mL) and analyzed by Dr. Mark Hail at Novatia LLC, 
Newtown, PA. Samples were analyzed on an Oligo HTCS equipped ESI/MS in negative mode. 
The data was obtained and deconvoluted using the ProMass software. Theoretical molecular 
weights were calculated by entering each sequence identity on IDT OligoAnalyzer. 
https://www.idtdna.com/calc/analyzer. 
2.5.3 Hybridization of RNA Sequences  
 A 50 µM stock solution of each RNA sample was prepared in autoclaved Millipore H2O. 
The templates (1 µL, 50 µM) were added to the each complementary RNA strand (1 µL, 50 µM) 
in 18 µL of the respective buffer conditions:  A) Tris-HCl buffer : 10 mM Tris-HCl, 100 mM NaCl, 
50 mM MgCl2, 1 mM EDTA (pH 8.0) (B) Phosphate Buffer :  5 mM Na2HPO4, 140 mM KCl, 1 
mM MgCl2 (pH 7.2)  (C)  MES buffer : 250 mM MES, 20 mM MgCl2 (pH 7.6)  (D)  30% Sucrose 
Tris-Acetate buffer : 89 mM Tris Acetate, 2.5 mM EDTA (pH 5.0), to afford the hybrid mixtures 
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(20 μL, 1 μM). The resulting mixtures were heated to 95 ºC for 3-5 minute in a heating block to 
denature any high-order structures. The samples were slowly cooled to room temperature (22 ºC) 
over 2 h followed by overnight storage in the refrigerator at 4 ºC prior to analysis. The RNA hybrid 
3CS prepared in this study are represented in Figure 2.7. 
2.5.4 Native PAGE Analysis of the RNA Hybrids 
 
With hybridized RNA sequences in hand, a native PAGE analysis was conducted in order 
to evaluate the possibility of RNA hybridization into the 3CS (Figure 2.8). The hybridized RNA 
samples (1 µM), in their respective annealing buffers, were suspended in non-denaturing 30% 
sucrose loading buffer (5 μL in 5X TBE). RNA hybrid samples were then loaded on an 18% native, 
non-denaturing PAGE and run at 300 V, 100 mA and 12 W for 2.5 h. Following electrophoresis, 
the RNA bands were visualized under UV shadowing (260 nm) and stained with a Stains-All 
(Sigma-Aldrich™) solution.  
2.5.5 Thermal Stability of RNA Hybrids 
All RNA hybrids were prepared as previously described in the RNA hybridization method. 
Thermal denaturation of the RNA hybrids was performed using a CARY 3E, UV-Vis 
spectrophotometer, with a temperature range of 5 – 95 ºC, at a temperature ramping rate of 0.5 ºC 
/min. The changes in absorption at 260 nm as a function of temperature were collected and the 
first derivative plot was used to determine the melting temperatures (Tm) of the RNA samples 
(Figure 2.9). The data was transferred and plotted in Microsoft Excel™ and reported as changes 
in the hyperchromicities (% H) observed at 260 nm as a function of temperature (5 – 95 ºC).  
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2.5.6 CD Spectroscopic Analysis of RNA Hybrids 
RNA hybrid samples were prepared as previously described. RNA samples were then 
transferred to fused quartz cells (1 cm path length) incubated at 10 ºC under N2 for 10 minutes 
prior to spectral acquisition. CD spectra were collected using an AVIV 62A DS CD 
spectrophotometer as an average of 3 scans with a 1.0 nm band width interval and a 0.5 nm step 
interval. CD spectra were analyzed in between 210 and 310 nm, blank corrected and smoothed 
prior to analyses (Figure 2.10). The raw data was exported into Microsoft Excel™ and plotted as 
changes in molar ellipticities (θ) with increasing wavelengths (210 – 310 nm). 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
2.6 RESULTS AND DISCUSSION 
The template RNA strands were designed and synthesized as 15-30 nt long sequences that 
favor Watson-Crick (WC) base pairing with the 15 nt and 23 nt long RNA complementary strands 
without producing self-folded structures. More specifically, three RNA template strands were 
designed and synthesized: RNAT15, RNAT20, and RNAT30 (4-6) to hybridize with two 
complementary RNA sequences RNAC15 and RNAC23 (8, 9). The hybridization of these RNA 
sequences into the putative 3CS was assessed by native PAGE in order to evaluate the influence 
of the length and base sequence composition of the guiding template strands and the 
complementary RNA sequences, in addition to the role of the buffer and its cation concentrations 
on hybrid RNA stability. The hybrid 3CS was found to be most favored in Tris buffer (Figure 
2.8A), based on the larger proportion of self-assembled RNAs that were found to be more retained 
on the gel relative to the non-hybrid sequences, which migrated faster and were visualized towards 
the bottom of the gel. The Tris buffer conditions contained the highest concentration of monovalent 
(Na+) and divalent (Mg2+) cations which have been reported to provide greater stability in RNA 
secondary and tertiary structure folding.63-66 Moreover, the combination of two complementary 
strands RNAC15 and RNAC23 (8, 9) that have RNA sequence lengths of 15 and 23 nt respectively, 
were found to have little hybridization propensity with the template sequence 4, RNAT15, 
composed of 15 nt. In this case, the poor hybridization and self-assembly can be attributed to 
minimal WC base pairing interactions between the pairing RNA strands (Figure 2.8, lanes 1). 
When the template strands were increased to 20 nt or greater, RNAT20, and RNAT30 (5-6) 
hybridization is observed with the complementary RNA sequences RNAC15 and RNAC23 (8, 9). 
The multiple bands observed in lanes 2 of the gel suggests the formation of duplex RNA hybrids 
with the 20 nt RNA template, RNAT20, (5) in place of the anticipated 3CS. The hybridization 
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propensity improves and favors the formation of the desired 3CS when the template strand is 
lengthened to a 30 nt RNA sequence RNAT30, (6) Figure 2.8, lanes 3. The 30 nt long RNA 
complementary strand formed a completely stable 3CS by effectively increasing the WC base-
pairing interactions. These lengthier sequences also contain a greater proportion of G:C base-pairs 
that contribute to more stable self-assembly. These trends were found to be consistent in 
phosphate, Tris and MES buffer conditions but with little hybridization detected in the sucrose 
buffer conditions (Figure 2.8). The self-assembled RNA hybrids were subsequently studied for 
their thermal stabilities (Tm) and structural (CD) properties.   
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Figure 2.8 Native 18% PAGE analysis for RNA 3-component hybrid system.  Analysis of RNA 
hybrid 3CS for the stability analysis. 3CS hybrid samples (0.75 μmol) were prepared by annealing 
equimolar quantities of complementary RNAs and template RNA sequences at 95 °C for 2-3 min 
in 20 µL of respective buffer followed by incubation (37 °C) for 14 h. (A) Tris-HCl buffer : 10 
mM Tris-HCl, 100 mM NaCl, 50 mM MgCl2, 1 mM EDTA (pH 8.0) (B) Phosphate Buffer :  5 
mM Na2HPO4, 140 mM KCl, 1 mM MgCl2 (pH 7.2)  (C)  MES buffer : 250 mM MES, 20 mM 
MgCl2 (pH 7.6)  (D)  30% Sucrose Tris-Acetate buffer : 89 mM Tris Acetate, 2.5 mM EDTA,(pH 
5.0).  Lanes 1-3: 3-component system using complementary RNA strands RNAC15 and RNAC23 
(8, 9) with RNA templates RNAT15, RNAT20 and RNAT30 (4-6), Lanes 4-6: RNA 15, 20, 30nt (4-
6), Lanes 7: RNA 38nt (7), Lanes 8, 9: RNA 15, 23nt (8, 9) complementary sequences. 
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The thermal denaturation of the hybrid RNA 3CS was tested in Tris, Phosphate MES and 
sucrose buffer conditions using UV-Vis spectrophotometry (Figure 2.9). In Tris buffer, the 
thermal denaturation data indicated a single phase duplex to single strand transition for the R2 
3CS, whereas little hybridization stability was observed for the R1 3CS and multiple transitions 
for the more stable R3 3CS. This data correlates nicely with the gel data observed in Figure 2.8A, 
which indicated little hybridization of the 3CS assembled with the shorter 15 nt RNA template and 
validated by the thermal denaturation curve of R1 3CS, duplex formation with the 3CS assembled 
with the 20 nt template and confirmed with the thermal denaturation curve of R2 3CS and a stable 
3CS RNA hybrid structure with the 30 nt RNA template which displayed multiple phase transitions 
in the case of R3 3CS. These results underscore the importance of the lengthy, 30 nt RNA template 
for the stable self-assembly of the RNA 3CS in Tris buffer conditions. The phosphate and MES 
buffer conditions indicated similar trends, albeit with lower Tm values observed for the helix-to-
coil transitions (Table 2.2). More specifically, a Tm: +9 ºC was observed for the R3 3CS in Tris 
buffer when compared with the MES buffer conditions. In addition, the Tm values of the R3 3CS 
also increased with the addition of divalent Mg2+ cations in the Tris buffer conditions, underscoring 
the importance of divalent cations on the stability of the hybrid RNA 3CS.  Comparatively, the 
sucrose buffer conditions failed to produce a thermally stable RNA hybrid. This result is 
unsurprising considering the lack of stabilizing counterions in the sucrose buffer. Taken altogether, 
the thermal denaturation experiments serves to support the hybridization trends delineated from 
the native PAGE assays. That is, the RNA 3CS effected by the hybridization of the template 30 nt 
RNA, RNAT30, (6) with the complementary RNA strands, RNAC15 and RNAC23 (8, 9) forms the 
most thermally stable RNA 3CS, R3 3CS, in Tris buffer (Figures 2.8 and 2.9).  
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Figure 2.9 Thermal denaturation of the RNA 3-component hybrid system.  The thermal stability 
of the RNA hybrid 3CSR1, R2 and R3 in (A) Tris-HCl buffer : 10 mM Tris-HCl, 100 mM NaCl, 
50 mM MgCl2, 1 mM EDTA (pH 8.0) (B) Phosphate Buffer :  5 mM Na2HPO4, 140 mM KCl, 1 
mM MgCl2 (pH 7.2)  (C)  MES buffer : 250 mM MES, 20 mM MgCl2 (pH 7.6)  (D)  30% Sucrose 
Tris-acetate buffer : 89 mM Tris Acetate, 2.5 mM EDTA, (pH 5.0). Data was collected on a Cary 
3E UV/Vis Spectrophotometer at 260 nm with temperature ranging from 5-90 ºC at a heating rate 
of 0.5 ºC/min. The data was transported to Excel and plotted as changes in hyperchromicity versus 
temperature. The Tm (ºC) of the curve was calculated from the first derivative plot which represents 
the value at which 50% of the hybrid dissociated to single strands. 
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Tris Buffer Tm (1) Tm (2) 
3CS R1: 
RNAC15+RNAC23+RNAT15 
55 ºC - 
3CS R2: 
RNAC15+RNAC23+RNAT20 
34 ºC 67 ºC 
3CS R3: 
RNAC15+RNAC23+RNAT30 
45 ºC 77 ºC 
Phosphate Buffer   
3CS R1: 
RNAC15+RNAC23+RNAT15 
51 ºC - 
3CS R2: 
RNAC15+RNAC23+RNAT20 
31 ºC 64 ºC 
3CS R3: 
RNAC15+RNAC23+RNAT30 
39 ºC 74 ºC 
MES Buffer   
3CS R1: 
RNAC15+RNAC23+RNAT15 
58 ºC - 
3CS R2: 
RNAC15+RNAC23+RNAT20 
67 ºC - 
3CS R3: 
RNAC15+RNAC23+RNAT30 
42 ºC 68 ºC 
30% Sucrose Buffer   
3CS R1: 
RNAC15+RNAC23+RNAT15 
47 ºC - 
3CS R2: 
RNAC15+RNAC23+RNAT20 
49 ºC - 
3CS R3: 
RNAC15+RNAC23+RNAT30 
44 ºC - 
 
Table 2.2 The thermal denaturation (Tm, ºC) data of the RNA hybrid 3CS in different buffer 
conditions. 
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The CD spectra, of the RNA hybrids in the tested buffer conditions generally maintained 
the canonical A-type RNA helical geometry (Figure 2.10). This conformation was characterized 
by the strong positive absorption bands at 260 nm and the negative absorption bands at 210 nm 
and in between 235-250 nm. The RNA hybrid R1 3CS formed with the 15 nt RNA template, 
RNAT15, 6, and the complementary RNA strands, RNAC15 and RNAC23 (8, 9) indicated a decrease 
in the molar ellipticities at these characteristic wavelengths. This result indicates a decrease in the 
stability of the A-type helical arrangement for the R1 3CS. When the template strand was 
lengthened to the 30 nt, RNAT30, 8, much more intense molar ellipticities were observed at 260 
nm and 235-250 nm correlating a stable A-type helix for the R3 3CS. The R3 3CS maintained a 
stable A-type helix in all buffer conditions indicating the importance of the lengthy RNA template 
strand in the preorganization of the RNA hybrid structure.   
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Figure 2.10 Circular dichroism spectra of the RNA 3CS R1, R2 and R3in (A) Tris-HCL buffer : 
10 mM Tris-HCl, 100 mM NaCl, 50 mM MgCl2, 1 mM EDTA (pH 8.0) (B) Phosphate Buffer :  5 
mM Na2HPO4, 140 mM KCl, 1 mM MgCl2 (pH 7.2)  (C)  MES buffer : 250 mM MES, 20 mM 
MgCl2 (pH 7.6)  (D)  30% Sucrose Tris-Acetate buffer : 89 mM Tris Acetate, 2.5 mM EDTA,(pH 
5.0). Circular Dichorism (CD) Spectrophotometer (Model: Aviv 62A DS). CD spectra were 
collected on an average of three scans using 1 nm bandwidth and 0.5 min step size at 25 ºC from 
310-210 nm. Samples were blank corrected, smoothed and the data converted to molar ellipticity 
values from the equation [θ] = θ /cl, where θ is the relative ellipticity (mdeg), c is the molar 
concentration of the 3CS (µM) and l is the path length of the cell (1 cm). The data was imported 
into Microsoft Excel and the CD spectra were plotted in terms of molar ellipticity vs wavelength. 
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2.7 CONCLUSIONS 
In this chapter, the stable three component (3CS) RNA hybridization conditions have been 
evaluated. The solid-phase synthesis of RNA was used to synthesize RNA template strands 
(RNAT15, RNAT20, RNAT30) and RNA complementary strands (RNAC15, RNAC23, RNAC30). All 
RNA sequences were purified by IP RP HPLC and their mass identities were confirmed by ESI-
MS. In order to promote a stable RNA three component hybrid system, the effect of the RNA 
template and complementary strands length and composition in varying buffer conditions were 
tested. The native PAGE analysis confirmed the hybridization capabilities of the RNA strands to 
generate the hybrid 3CS. Furthermore, the thermal denaturation experiments confirmed the 
thermal stability of the RNA hybrid 3CS containing the 30 nt template strand, RNAT30 hybridized 
with the complementary 15 and 23 nt RNA strands, RNAC15, RNAC23 in Tris buffer. The RNA 
hybrid 3CS secondary structures were confirmed as A-type helical geometries by CD 
spectroscopy. This data also confirmed the most stable helical arrangement for the RNA 3CS 
composed of the template 30 nt RNA along with the complementary 15 nt and 23 nt RNA strands 
in Tris buffer conditions.  This study revealed the importance of RNA hybridization conditions in 
the design of RNA self-assembled hybrids. These structures may have biological importance and 
therapeutic relevance for cancer gene therapy applications (Chapter 3). 
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CHAPTER 3: RNAi NANOTECHNOLOGY: APPLICATIONS OF 
siRNA NANOSTRUCTURES IN RNAi SCREENING AND CANCER 
GENE THERAPY  
3.1 ABSTRACT 
The emerging field of RNA nanotechnology has been used to design well-programmed, self-
assembled nanostructures for applications in chemistry, biology and medicine. At the forefront of 
its utility in cancer is the unrestricted ability to self-assemble multiple siRNAs within a single 
nanostructure formulation for the RNAi screening of a wide range of oncogene targets while 
potentiating cancer gene therapy effects. In our RNAi nanotechnology approach, V- and Y-shape 
RNA templates were designed and constructed for the self-assembly of discrete, higher-ordered 
siRNA nanostructures targeting the oncogenic glucose regulated chaperones. The GRP78-
targeting siRNAs self-assembled into genetically encoded spheres, triangles, squares, pentagons 
and hexagons of discrete sizes and shapes according to TEM imaging. Furthermore, gel 
electrophoresis, thermal denaturation and CD spectroscopy validated the prerequisite siRNA 
hybrids for their RNAi application. In a 24 sample siRNA screen conducted within the AN3CA 
endometrial cancer cells known to overexpress tumorigenic GRP78, the self-assembled siRNAs 
targeting multiple sites of GRP78 mRNA demonstrated more potent and long-lasting anticancer 
activity relative to their linear controls. Extending the scope of our RNAi screening approach, the 
self-assembled siRNA hybrids (5 nM) targeting of GRP-75, 78 and 95 resulted in significant (50-
95%) knockdown of the glucose regulated chaperones, which led to synergistic effects in tumor 
cell cycle arrest (50-80%) and death (50-60%) within endometrial (AN3CA), cervical (HeLa) and 
breast (MDA-MB-231) cancer cell lines. Interestingly, a non-cancerous lung (MRC5) cell line 
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displaying normal glucose regulated chaperone levels was found to tolerate siRNA treatment and 
demonstrated less toxicity (5-20%) relative to the cancer cells that were found to be addicted to 
the glucose regulated chaperome. These remarkable self-assembled siRNA nanostructures may 
thus encompass a new class of potent siRNAs that may be useful in screening important oncogene 
targets while improving siRNA therapeutic efficacy and specificity in cancer. 
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3.2 INTRODUCTION 
3.2.1 Discovery and Functions of GRPs 
The discovery of the Glucose Regulated Proteins (GRPs) in 1977 by Pastan and co-workers 
occurred thorough the keen observation that two proteins of 78 and 94 KDa were strongly induced 
in chicken embryo fibroblasts cultured in glucose-free medium.1 These proteins were subsequently 
identified as GRP78 (also referred to as the immunoglobulin binding protein Bip and HSPA5) and 
GRP94 (also identified as gp96 and HSP90B1). GRP94 is the most abundant glycoprotein in the 
endoplasmic reticulum (ER). GRP78 is evolutionarily conserved from yeast to humans and 
abundantly located in the lumen of the ER. Although GRP78 and GRP94 are primarily located in 
the ER, they are also found in several other subcellular compartments such as the mitochondria, 
the plasma membrane and the cytosol where they display a myriad of functions. Another important 
GRP includes GRP75 (also known as mortalin/heat shock protein 70, HSP70/HSPA9) which was 
first identified and characterized by Welch and co-workers in 1989.2 GRP75 is primarily localized 
in the mitochondria, and related forms may also be found in the cytosol or on the surface of the 
extracellular membrane. The glucose regulated proteins, GRP-75, 78 and 94 are stress-inducible 
molecular chaperones belonging to heat-shock protein (HSP) family.3 The GRPs serve multiple 
functions related to chaperoning ER protein translocation, folding, quality control and export to a 
variety of organelles for function. The GRPs own subcellular localization is in the endoplasmic 
reticulum where it chaperones protein folding activity, in the mitochondria where it interacts with 
pro-apoptotic executors and at the cell surface where it directs cell signaling activity.11 More 
specifically, GRPs guide misfolded proteins towards processing and degradation by the unfolded 
protein response (UPR) mechanism and can signal a variety of anti- and pro-apoptotic pathways 
(i.e. caspase activation) that regulate cell survival (Figure 3.1). In the UPR mechanism, ER stress 
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signaling stimulates the release of sequestered GRP78 from protein kinase like ER kinase (PERK), 
inositol requiring enzyme 1 (IRE1) and activating transcription factor 6 (ATF6).11-14 This results 
in PERK-catalyzed phosphorylation of the eukaryotic initiation factor 2 alpha (eIF2), preventing 
the translocation of additional proteins in the ER for protein translation.13 Dimerization of IRE1 
results in endoribonuclease activity which splices XPB1 mRNA for the expression of a basic 
leucine zipper family of transcription factors that assists in the production of chaperone proteins.14 
Similarly, ATF6 is cycled into the Golgi where it is cleaved and released into a functional 
transcription factor that promotes the expression of the GRPs that assists in protein folding as part 
of the UPR mechanism.12 In this manner, the UPR elevates GRP expression levels and activity to 
release the ER biosynthetic burden in stressed cells.11 Therefore, GRPs are known to maintain 
cellular integrity and homeostasis under physiological or pathological stress conditions. During 
physiological stress in the presence of misfolded proteins, hypoxia, embryonic development and 
aging, GRPs bind ATP to regulate Ca2+ flux and to facilitate protein folding events which inhibits 
the activation of pro-apoptotic executors and maintains normal cellular function under stressed 
conditions.3-5 Therefore, the GRPs function as part of a cluster of proteins referred to as the 
chaperome which surveils cellular insults under stressed conditions and mitigates their impact on 
cellular malfunction. Therefore, GRP induction is an indicator of ER stress and many studies have 
revealed their activation mechanisms and intracellular signaling pathways.4,5 Cellular stress due to 
protein misfolding occurs by intrinsic and extrinsic factors, including altered cell metabolism, 
hyperproliferation, hypoglycemia, hypoxia, acidosis, viral infection and genetic lesions that may 
also lead to cancer initiation.3,9   
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Figure 3.1 GRPs function in unfolded protein response and stress response. Figure has been 
adapted from ref 15: Lee, A.S. Nat. Rev. Cancer 2014, 14, 263-276. 
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3.2.3 Roles of GRPs in Cancer 
Due to their induction during pathological stress conditions, GRPs have also been 
implicated in tumorigenic activity. Many studies have shown that the aggressive growth and 
invasive properties of many cancer types are due to the distinctive functions of GRP 
overexpression, especially related to GRP-75, 78 and 94 (Table 3.1).15 For example, GRP78 
regulates cancer cell viability and apoptosis by maintaining a balance in between ER protein 
folding events and the release of pro-apoptotic executors from their inactive state.6  While GRP94 
has been found to be essential in the processing of proteins that have been implicated in 
tumorigenesis, such as the insulin-like growth factor 1 (IGF-1), Toll-like receptors (TLRs) and 
integrins.7 Also, GRP75 interacts with the tumor suppressor p53, inactivating the capacity of p53 
to arrest cell growth and to trigger apoptosis at the onset of cancer.8  
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Table 3.1 Overexpression of GRPs in different types of cancers. Table adapted from reference 15, 
Lee, A.S. Nat. Rev. Cancer 2014, 14, 263-276. 
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GRP78 has been found to play a pivotal role in promoting the inhibition of cell apoptosis 
under pathological stress conditions that have resulted in the progression, invasion and the rise of 
treatment resistance of cancer.15 Contributing to the pathological role of GRP78 in cancer is an 
overexpression and cell surface localization which functions as a signaling receptor for oncogenic 
activity.16  Interestingly, GRP-75, 78 and 94 have all been found on the surface of cancer cell types 
but not on normal tissues making them clinically relevant biological markers for the specific 
detection and treatment of cancer.17 Moreover, GRP78 is associated with other stress-inducible 
members of the GRP family of chaperones, including GRP-75 and 94 which altogether form 
members of the cancer chaperome that contributes to the progression of some of the most 
aggressive and resilient forms of cancers.15 Thus, GRPs play important roles in regulating a variety 
of essential functions in cancer through a UPR-dependent and independent manner. As an ER 
chaperone, GRP78 controls processing and maturation of a wide range of cell surface receptors 
and secretory proteins that are crucial for the ability of cancer cells to respond to extrinsic 
proliferative signals.3 Furthermore, GRP78 has also been found to stabilize Wnt-β-catenin in the 
ER by regulating Wnt proliferative signaling.18 Under hypoxic conditions GRP78 dissociates from 
Wnt inhibiting its function leading to proteasome degradation and reduced Wnt secretion. GRP78 
has also been implicated in protein transport, such as the MTJ-1 (murine tumor cell DnaJ-like 
protein 1) in macrophages and PAR-4 (Prostate apoptosis response 4), which promotes cancer cell 
proliferation.19,20 GRP78 also serves as a multifunctional receptor in prostate cancer cells in the 
activated form with the plasma proteinase inhibitor α2-macroglobulin (α2-M*), which triggers 
ERK (extracellular signal-regulated kinases) and AKT (also known as Protein kinase B, PKB) 
activation. This signaling pathway results in increased levels of DNA and protein synthesis that 
contribute to cancer cell proliferation and the inhibition of apoptosis.21,22 In human leukemic cells, 
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the overexpression of GRP78 led to increased PI3K (Phosphoinositide 3-kinase) and PIP3 
(Phosphatidylinositol (3,4,5)-trisphosphate) production.23 Cell surface interactions in between 
GRP78 and Cripto-1 (also known as teratocarcinoma-derived growth factor 1) have also been 
implicated in the activation of the oncogenic MAPK and PI3K pathways and modulating activing-
A, activing-B, nodal and transforming growth factor-β1 signaling activity.24  
GRP94 controls the maturation and secretion of the important mitogenic insulin growth 
factors, IGFs which leads to the activation of the oncogenic PI3K-AKT cell growth signaling 
pathway.25 Deletion of GRP94 in B-cells26 and macrophages27 have resulted in the attenuation of 
multiple myeloma and inflammatory colorectal cancer. Conversely, GRP94 overexpression was 
shown to enhance the growth of breast cancer cells under chronic exposure to reactive oxygen 
species (ROS).28 This effect was counteracted by the production of antioxidants and the formation 
of disulfide bonds in proteins located in the ER.28 The down-regulation of p53 target genes such 
as Cdkn1a and Mdm2 have also been correlated with an overexpression of GRP75. In this case, 
GRP75 functions as a mitochondrial protein importer due to its ability to sequester p53 in the 
cytoplasm of neuroblastomas.29 The mitogenic activities of fibroblast growth factor-1 (FGF-1) in 
association with GRP75 has also shown enhanced endothelial cell migration and proliferation.30   
 Recently, a close functional relationship between the GRP78, the pro-apoptotic protein 
BIK (BCL2 interacting killer) and anti-apoptotic protein BCL-2 (B-cell lymphoma 2) suggests that 
GRP78 and BCL-2 form separate complexes with the different domains of BIK.31 The high levels 
of GRP78 resulted in BIK sequestration, which led to the inhibition of the BCL-2:BIK binding 
interaction, resulting in the relocation of the downstream pro-apoptotic protein BAX (Bcl-2-
associated X protein) into the mitochondria. This led to the inhibition of cytochrome c release into 
the cytosol which prevented cellular apoptosis and triggered oncogenic activity in breast cancer.31 
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Moreover, cell surface GRP78 along with PAR4 (Protease-activated receptor 4) prevents TNF-
related apoptosis-inducing ligand (TRAIL) apoptosis activation in HeLa20 and MDA-MB-23132 
cells and therefore functions as a pro-survival factor. GRP78 and GRP94 overexpression is 
associated with lymph node metastasis and carcinoma recurrence, and silencing of GRP94 was 
found to inhibit migration and proliferation of MDA-MB-231 breast cancer cells in vitro.28 More 
recently, the whole cell surface expression levels of GRP78 and GRP94 in HeLa cells were 
observed following treatment with BFA (brefeldin A) in the absence and presence of the ER stress 
stimuli Tg (thapsigargin) and Tu (tunicamycin). This treatment resulted in suppressed cell surface 
expression of GRP78 and GRP94.33 The effect of chemotherapy drugs on MDA-MB-231 breast 
cancer cells was enhanced by siRNA mediated silencing of GRP78, which was implicated in drug 
resistance.34 In comparison with normal healthy cells, GRP75/Mortalin was significantly up-
regulated in the cytoplasm of breast cancer MDA-MB-231 cells according to an 
immunofluorescence (IF) assay.35 Therefore, Mortalin/GRP75 has also been implicated as a 
biomarker for cancer therapy and for the prognostic evaluation of breast cancer progression.35 The 
overexpression of Mortalin/GRP75 protein coincides with the acquisition of invasiveness, 
contribution to proliferation, anti-apoptosis, ATP production, chaperoning and inactivation of 
tumor suppressor p53 and PI3K/AKT activities.36 Targeting of Mortalin by siRNA37, ribozymes38 
and small molecules39 resulted in growth arrest and led to apoptosis of cancer cells. Another 
interesting study showed the functional role and mechanism of cell surface GRP75 in HSPG 
(heparan sulfate proteoglycan core protein) mediated endocytosis of macromolecule magnetic 
nanoparticles in HeLa cells.40 Interaction between caspase-7 and GRP78 at the ATP-binding site 
leads to inhibition of apoptotic event. (-)-Epigallocaterchin Gallate (EGCG) treatment of 
etoposide-treated MDA-MB-231 cells prevented the formation of the inhibitory complex 
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compromising endogenous GRP78 and caspase-7, which contributed to development of drug 
resistance.41 The overexpression of wild-type tumor suppressor BRCA1 (breast cancer 1)  was 
found to suppress the expression of GRP78 in cancer cells. siRNA mediated silencing of BRCA1 
showed enhanced level of GRP78, GRP94 and CHOP indicating survival of cancer cell by GRP-
78 and 94. The simultaneous knockdown of GRP78 and BRCA1 by siRNA showed increase 
sensitivity towards apoptosis in breast cancer cells (MDA-MB-231, MCF-7) and ovarian cancer 
cells (OVCAR-3).42 Moreover, GRP78 overexpression also been linked with the progression of 
endometrial cancer (EC). GRP78 has been implicated in EC cell proliferation according to cell 
cytotoxicity and proliferation assays which underscored the role of GRP78 within the AN3CA EC 
cells. Reduction of GRP78 by siRNA knockdown was found to attenuate the invasion rate and led 
to the inhibition of cell growth resulting in apoptosis in EC cells.43,44 Thus, GRP knockdown or 
inhibition has been shown to sensitize cancer cells to treatment, trigger tumor cell cycle arrest and 
apoptosis resulting in potent anticancer effects.15,28,45-49 Thus, GRP78 and the related GRPs have 
been validated as clinically relevant molecular targets in cancer.15   
3.2.4 siRNA Nanostructures for Cancer Gene Therapy  
Gene therapy has re-emerged as a powerful modern day treatment modality in the search 
for a cure for cancer.50 Several cancer gene therapy methods have already been realized in vitro, 
as well as in vivo, paving the way for their successful use in human clinical oncology.51  Leading 
the way are the growing applications of siRNA in cancer therapy.52 Technological advances in 
synthetic biology have ushered in a new wave of modified siRNAs that have improved the 
silencing of oncogenic mRNA expression ultimately resulting in tumor cell death.53 This RNAi 
mechanism has shown exceptional catalytic efficacy and tolerance for a wide range of modified 
75 
 
siRNAs that can effectively screen a variety of oncogene targets while potentiating gene silencing 
effects.54  
The rise of RNA nanotechnology has led to the evolution of functional RNA materials for 
a variety of applications, including the development of nanomedicines.55,56 Recently, siRNA 
nanostructures have been formulated and applied for silencing single or multiple gene targets. For 
example, hybrid RNA nanocubes composed of six double-stranded dsRNA Dicer substrates have 
been formulated and shown to simultaneously release multiple siRNAs in breast cancer cells upon 
Lipofectamine-mediated transfection.57 The intracellular release of the siRNAs was found to 
trigger the RNAi response and effectively down-regulated the reporter, enhanced green fluorescent 
protein, (eGFP) for up to twelve days. In a related case study, multifunctional RNA nanorings 
embedding six siRNAs within the nanoparticle formulation were shown to silence eGFP 
expression at concentrations as low as 1 nM.58 Moreover, the siRNA nanoparticles were 
functionalized with RNA aptamers which were selected for binding to the epidermal growth factor 
receptor (EGFR) overexpressed on human breast cancer cells. These RNA nanoparticles 
demonstrated targeted tumor binding and cellular uptake, which led to persistent eGFP knockdown 
over a nine day period. This effect was found to be equivalent to the transfection of the linear 
eGFP-siRNAs at six-fold higher concentrations. In another proof-of-concept study, the branched 
siRNA nanostructures targeting multiple mRNA sites of the luciferase firefly reporter gene were 
shown to self-assemble into three- and four-way junctions.59 These nanoparticle formulations 
released multiple siRNAs upon Dicer cleavage and effectively silenced luciferase activity for up 
to five days in HeLa cells. Taken altogether, these representative examples demonstrate the ability 
for higher-ordered siRNA nanostructures to behave as Dicer substrates, resulting in the release of 
multiple siRNAs that are processed by the RNAi mechanism, ultimately leading to synergistic 
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gene knockdown effects. These results underscores the potential utility of siRNA nanostructures 
in RNAi screening and cancer gene therapy applications.  
 
Figure 3.2 Assembly of GRP78 targeting V-shape, Y-branch and >-< hyperbranch siRNAs based 
on the ribouridine branchpoint phosphoramidite synthon.60  
 
We previously reported the synthesis, characterization and RNAi evaluation of branch and 
hyperbranched siRNAs (Figure 3.2).60 These novel molecular structures were built by semi-
automated solid phase RNA synthesis and incorporated a branchpoint synthon which facilitated 
the extension of single or double siRNAs targeting the GRP78 oncogene. The branch and 
hyperbranch siRNAs led to 50-60% silencing of GRP78 expression which translated to 
approximately 20% cell death of the HepG2 liver cancer cells.60 Therefore, the branch and 
hyperbranch siRNAs have effectively extended the repertoire of modified siRNA motifs that may 
be useful in the development of more potent RNAi oncogene therapeutics.  
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3.3 PROJECT OBJECTIVES 
Inspired from previous studies in RNA nanotechnology, this chapter will discuss the 
synthesis, characterization and biological assessment of siRNA nanostructures in human cancer 
cell lines. The study begins with the design of linear, V-shape and Y-shape RNA templates which 
target one, two or three sites of oncogenic GRP78 mRNA and those related to the GRP-75 and 94 
mRNA sequences.49,61 The assembly of the complementary linear, V-shape and Y-shape RNA 
sequences is based on the canonical Watson-Crick Base-pairing interactions that results in the 
formation of hybrid structures. Moreover, the RNA templates function as guide strands, that pre-
organize the self-assembly of hybrid siRNA into higher-order structures having distinct sizes and 
shapes (Figure 3.3). The solid-phase RNA synthesis strategy based on our previous study60 was 
used to generate V-shape and Y-shape RNA templates using the ribouridine branch-point synthon 
(Figure 3.2). LCMS was used to characterize the purity and identity of the RNA templates for 
their self-assembly capabilities. The proposed hybrid siRNA nanostructures were characterized by 
Polyacrylamide Gel Electrophoresis (PAGE), Thermal Denaturation (Tm) and Circular Dichroism 
Spectroscopy (CD). The siRNA nanostructures were imaged by Transmission Electron 
Microscopy (TEM) to provide their distinct shapes and size distributions. Moreover, the 
application of siRNA nanostructures in cancer cell biology was screened within EC (AN3CA), 
cervical (HeLa), breast (MDA-MB-231) and within a non-tumorigenic, control lung cell line 
(MRC5). The study began with the optimization of siRNA transfections using RNAiMAX™, 
Lipofectamine 2000™ and SilenFect™ within AN3CA EC cells. Next, a 24-siRNA sample screen 
was conducted within the AN3CA cells to determine the structure-activity relationships (SARs) of 
the GRP78-targeting siRNAs. The most promising siRNA leads were then selected to further 
investigate the RNAi mediated GRP78 silencing efficiency. Finally, the most potent Y-shape 
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siRNA was synthesized for the synergistic knockdown of GRPs (GRP78, GRP94, GRP75), within 
the GRP overexpressing HeLa (cervical cancer cells), MDA-MB-231 (breast cancer cells), and 
AN3CA (endometrial) cancer cells and also within the non-cancerous MRC5 (epithelial normal 
lung) cells displaying normal GRP function. This study will describe a correlation of the GRP 
silencing effects of the siRNAs with their observed anti-cancer activities. Taken altogether, this 
combinatorial self-assembly approach has enabled the formulation of a library (30) of siRNA 
nanoparticles for exploring SARs within GRP overexpressing cancer cell lines. 
 
 
Figure 3.3 Design and self-assembly of siRNA nanostructures. The RNA templates, namely, 
linear, V- and Y-shaped RNA were designed and synthesized according to our previously 
described methodology.56 The V- and Y-shaped templates incorporate a branchpoint ribouridine 
(rU) which facilitates the incorporation of sense (S) and antisense (A) RNA. These templates 
preorganize the self-assembly of siRNA hybrid nanostructures having discrete sizes and shapes, 
including those belonging to circles, triangles, squares, rectangles, pentagons, hexagons and 
porous-type structures. These siRNA nanostructures are genetically encoded to target a single (1), 
double (1, 2) and triple (1, 2, 3) sites of oncogenic GRP-75, 78 and 94 mRNA.
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3.4 EXPERIMENTAL SECTION 
3.4.1 Solid Phase Synthesis, Cleavage and Deprotection of Linear, V- and Y-shape siRNAs  
Synthesis of linear siRNAs were accomplished on the ABI solid-phase RNA synthesizer 
as previously described in Chapter 2. The solution phase synthesis of orthogonally protected 5’-
OLv 2’-OMMT ribouridine phosphoramidite and its incorporation into branch siRNA structures 
by solid phase RNA synthesis have also been reported in an earlier study.60 Taking full advantage 
of this existing methodology, the synthesis of V-shape and Y-shape RNA templates and their 
complementary sequences Table 3.2, were completed on solid-phase. Briefly, the synthesis 
strategy involves RNA synthesis on the CPG up to the branchpoint ribouridine. The 
decyanoethylation step using 4:6 v/v Et3N:MeCN for 90 min was used to remove the phosphate 
protecting groups in order to make the more stable phosphodiester bond. The next step involved 
the removal of 2’-MMT protecting group at the branchpoint position. The detritylation reaction 
was accomplished using 3% DCA:DCM for 3 min to ensure complete deprotection. Elongation of 
the second RNA sequence at the liberated 2’-OH of the branchpoint synthon afforded the V-shape 
RNA template. A capping step, resulting in acetylation of the terminal 5’-hydroxyl group was 
completed in order to prevent side-reactions. The 5’-Lv group at the branchpoint position was 
removed using 0.5M NH2NH2
.H2O, buffered in 3:2 v/v pyridine:acetic acid for 20 min. Synthesis 
of the third RNA strand from the branchpoint 5’-position led to the generation of the Y-shape RNA 
template.  Following synthesis, the RNAs were cleaved and deprectected from the CPG solid 
support. Deprotection of the exocyclic amino nucleobase and cyanoethyl phosphate protecting 
groups were accomplished using 7:3 v/v NH4OH: EtOH at 60 ºC for 12-14 h. The 2’-TBDMS 
protecting groups was desilylated using 1:1.2 v/v trimethylamine-trihydrofluoride TEA-
3HF:DMSO at 55 ºC for 2 h. Finally the crude RNA pellets were precipitated in 3M NaOAc (25 
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µL) and n-BuOH (1 mL). The crude RNA pellets were dissolved in autoclaved, Millipore H2O for 
analysis and purification.  
 
3.4.2 RP IP HPLC  
The crude RNA templates were analyzed by Reverse Phase Ion Pairing High Performance 
Liquid Chromatography (RP IP HPLC) to determine crude purities. Briefly, HPLC analyses (0.1 
OD) and purifications (1 OD) were performed on a Waters® 2695 Alliance Separations Module. 
Crude RNA templates were dissolved in autoclaved water (1 mL) and injected into a Waters® 
Symmetry C-18 reverse phase column (4.6 x 150 mm, 5 μm particle size, 120 Å) heated at 60 ºC. 
HPLC analyses and purifications were conducted using a gradient of 5-95% eluent B (20% 
acetonitrile in 0.1 M triethylammnonium acetate) in eluent A (0.1 M triethylammonium acetate). 
The HPLC flow rate was set at 1 mL/min, with run times of 26 min and with absorbance detection 
at 260 nm using a Waters® 2489 UV/Visible detector. Retention times (min.) and peak areas (% 
area) were integrated with Empower II software (Waters®) and used to confirm RNA purities≥96% 
following sample purifications. 
3.4.3 Mass Spectrometry 
  RNA templates (0.1-0.4 μM) were dissolved in millipore water (1 mL) and analyzed by 
Dr. Mark Hail at Novatia LLC, Newtown, PA. Samples were analyzed on an Oligo HTCS 
equipped ESI/MS in negative mode. The data was obtained and deconvoluted using ProMass 
software. Theoretical molecular weights were calculated by entering each sequence identity on 
IDT OligoAnalyzer. https://www.idtdna.com/calc/analyzer 
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3.4.4 siRNA Hybridization 
  A 50 µM stock solution of each RNA sample was prepared in autoclaved Millipore H2O. 
To the templates (20 µL, 50 µM) was added the complementary RNA strands (20 µL, 50 µM) and 
annealing buffer (60 µL, 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM EDTA) to afford the 
hybrid mixtures (100 μL, 10 μM). The resulting mixtures were heated to 95 ºC for 3-5 min on a 
heating block, slowly cooled to room temperature (22 ºC) over 2 h and stored in the fridge at 4 ºC 
overnight (12- 14 h) prior to analysis. 
3.4.5 Non-denaturing, Native Polyacrylamide Gel Electrophoresis (PAGE) 
The hybridized siRNA samples (20 µM) in annealing buffer (10 mM Tris, 50 mM NaCl, 1 
mM EDTA, pH 7.5–8.0, 8 µL) were suspended in 30% sucrose loading buffer (15 μL in 5X TBE). 
Samples were then loaded on a 16% native, non-denaturing PAGE and run at 300 V, 100 mA and 
12 W for 2.5 h. Following electrophoresis, the siRNA bands were visualized under UV shadowing 
(260 nm) and stained with a Stains-All (Sigma-Aldrich™) solution. 
3.4.6 Thermal Denaturation (Tm) 
  All siRNA hybrids were prepared as previously described in annealing buffer (0.75 µM, 
10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5–8.0, 1 mL). Thermal denaturation of the siRNA 
hybrids was performed using a CARY 3E, UV-Vis spectrophotometer, from 5 – 95 ºC, with 
temperature ramping of 0.5 ºC /min. The changes in absorption at 260 nm as a function of 
temperature was collected and the first derivative plot was used to determine the melting 
temperatures (Tm) of the siRNA samples. The data was transferred and plotted in Microsoft 
Excel™ as changes in the hyperchromicities (% H) observed at 260 nm as a function of 
temperature (5 – 95 ºC).  
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3.4.7 CD Spectroscopy 
siRNA samples were hybridized in annealing buffer (0.75 µM, 10 mM Tris, 50 mM NaCl, 
1 mM EDTA, pH 7.5–8.0, 1 mL) as previously described. Samples were then transferred to fused 
quartz cells (1 cm path length) and incubated at 10 ºC under N2 for 10 minutes prior to spectral 
acquisition. CD spectra were collected using an AVIV 62A DS CD spectrophotometer as an 
average of 3 scans with a 1.0 nm bandwidth interval and a 0.5 nm step interval. CD spectra were 
analyzed in between 210 and 310 nm, blank corrected and smoothed prior to analyses. The raw 
data was exported into Microsoft Excel™ and plotted as changes in molar ellipticities (θ) with 
increasing wavelengths (210 – 310 nm). 
3.4.8 TEM Imaging 
siRNA hybrid samples (50 µL, 50 µM) were suspended in sodium phosphate buffer (50 
mM, pH 7, 1 mL) and sonicated for 15 minutes for complete dissolution. Samples were then mixed 
in 1:1 v/v ratio with 1% uranyl acetate and sonicated for an additional 10 minutes. An aliquot (5 
µL) of siRNA sample was placed on a carbon film coated copper grid, 300 mesh (Electron 
Microscopy Sciences Inc., Hatfield, PA) dried overnight and viewed under the transmission 
electron microscope (JEOL, model JEM-1200 EX). Images were taken with a SIA–L3C CCD 
camera (Scientific Instruments and Applications, Inc.) using the software Maxim DL5 (Diffraction 
Limited, Ottawa, Canada). TEM images were collected by Dr. Reeta Yadav and Suiying Huang in 
collaboration with the research group of Dr. Uri Samuni at Queens College in Flushing NY.  
3.4.9 Cell Culture 
  The human normal lung cells MRC5 (ATCC® CCL-171™), endometrial cancer cells 
AN3CA (ATCC® HTB-111™), breast cancer cells MDA-MB-231 (ATCC® HTB-26™) and 
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cervical cancer cells HeLa (ATCC® CCL-2™) were purchased from ATCC. All cell based 
experiments were conducted under the supervision of Drs. John Koren and Gabriela Chiosis at the 
Memorial Sloan Kettering Cancer Center in New York, NY. The MDA-MB-231, HeLa and MRC5 
cells were cultured in Dulbecco’s Modified Eagle medium (DMEM) while AN3CA cells were in 
Minimum Essential Medium (MEM) supplemented with 10% (v/v) Fetal Bovine Serum (FBS) and 
1% (v/v) penicillin/streptomycin (P/S) under 5% CO2 at 37 ºC.  For passaging cells were detached 
with 0.25% trypsin and re-suspended with complete culture medium. 
3.4.10 Serum Stability Assay 
siRNA hybrid samples (A1:S1, A12:S1:S1, A12:S12 and A123:S1:S2:S3) were hybridized 
as previously described in annealing buffer (0.75 µM, 10 mM Tris, 50 mM NaCl, 1 mM EDTA, 
pH 7.5–8.0, 1 mL). An aliquot (10 µL, 5 µM) was added to a 10% FBS solution (40 µL in 
phosphate buffer). The mixtures were incubated at 37 ºC and periodically (0 – 48 h) sample 
aliquots (10 μL) were removed and suspended in 1.5X TBE loading buffer (15 µL) and frozen at 
-80 ºC prior to analyses. Samples were thawed to room temperature (22 ºC) and analyzed on a 16% 
native, non-denaturing PAGE for 2.5 h. The gel was then visualized with a Stains-All (Sigma-
Aldrich™) solution.  
3.4.11 siRNA Transfections in AN3CA Cells 
Briefly, the AN3CA endometrial cancer cells (ATCC® HTB-111™), 1 x 105, were plated 
in 6-well culture plates containing MEM culture media with 10% FBS. Cells were cultured for 48 
h in a humidified incubator set at 37 ºC with 5% CO2. Prior to transfections, the siRNA hybrids (5 
µL, 2.5-12.5 µM, in DMEM, 250 µL) were mixed with the transfection reagents (Lipofectamine 
2000™, SilentFect™ or RNAiMAX™, 2.5 – 7 µL in DMEM, 250 µL) according to the 
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manufacture’s recommendation. The mixtures were incubated (10 min, 22 ºC) then added to the 
AN3CA cell culture and incubated at 37 ºC with 5% CO2 over a three-day period. Cell growth 
over time (65-72 h) was monitored in an Incucyte™ (Essen BioScience). 
 
3.4.12 Western Blots 
The cell media was aspirated from the transfected culture and washed with PBS buffer for 
2-3 min, twice.  The cells were lysed using cell lysis buffer (1% Tween-20, 50 mM Tris, 130 mM 
NaCl, 5 mM EDTA) containing protease inhibitors and phosphatase inhibitors (Protease inhibitor, 
PSMF, Phos2, Phos3).  Protein concentrations of lysates were determined using the BSA protein 
assay reagent (ThermoFisher Scientific Inc.). Proteins samples (15-20 mg, 20 µL) were dissolved 
in 5X loading buffer, boiled for 5-7 min, and resolved in 10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were electrotransferred onto a 
polyvinylidene difluoride membrane (Bio-Rad Laboratories), which was blocked in Tris-buffered 
saline, pH 8.0, Tween-20, 5% (w/v) skimmed milk (TBST solution) for 1 h at room temperature 
(22 ºC). Membranes were then probed with the indicated primary antibodies (anti-PARP p85 
fragment pAb, Promega Inc.; anti-GRP75 mAb, ThermoFisher Scientific Inc and anti-GRP94 
pAb; anti-GRP78 pAb, Cell Signaling Inc.) in TBST solution at 4 ºC overnight. Next day, 
membranes were washed with TBST solution (3X, 10 min each) and incubated with horseradish 
peroxidase conjugated secondary antibodies (1:3000 v/v) at room temperature for 1 h followed by 
washing with TBST solution (3X, 10 min each). Immunoblotted protein bands were visualized by 
enhanced chemiluminescence reagent (ThermoFisher Scientific Inc.) and quantified using NIH 
imager (ImageJ). 
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3.4.13 Cell Cytotoxicity 
Following transfection with GRPs specific siRNAs, a cytotoxicity assay was performed 
with all cells using the Cytotoxicity Detection Kit (ThermoFisher Scientific Inc.). With this kit, 
the rate of cell lysis was monitored by determination of the LDH amount released into the culture 
medium and quantified at 492 nm by the detection of the red formazan chromophore. 
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3.5 RESULTS AND DISCUSSION 
3.5.1 siRNA Self-Assembly 
The siRNA sequences described in this study (Table 3.2) are based on the target 
nucleotides for down-regulating GRP-75, 78 and 94 expression in human cancer cells.49,61 The 
linear, V- and Y-shaped RNA templates were synthesized by semi-automated solid phase RNA 
synthesis following our previously reported procedure.60 The RNA templates were purified by 
Reverse-Phase Ion-Pairing High Performance Liquid Chromatography (RP IP HPLC) in ≥96% 
purities and their identities were confirmed by electrospray ionization mass spectrometry (ESI MS) 
(Table 3.2). 
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Table 3.2  a Linear sequence number 1,2,3,7,19 and 21 represents antisense (A) siRNA sequence 
to its complimentary sense (S) sequences 4,5,6,8,20 and 22 respectively. V-shaped siRNA 
sequences 9-14 contains two siRNA sequences targeting GRP78 mRNA. Y-shaped siRNA 
sequences 15-18 contains three siRNA sequence targeting three different sites of GRP78 mRNA. 
Sequences 19-22 are linear siRNA sequences targeting GRP94 and GRP75. Sequences 23-25 are 
V-shape siRNA targeting two GRP mRNAs and sequence 26 is a Y-shape siRNA targeting three 
GRP mRNAs (GRP78, GRP94, GRP75).  b Determined by UV-Vis Spectroscopy. c Obtained by 
RP-IP-HPLC using 0.1 mM TEAA in 0-20% MeCN, pH: 7.2 over 26 min. d Calculated mass 
(observed mass) by ESI-MS in negative mode (Novatia LLC, Newton, PA). 
 
 Based on the previous study on the requirements for stable 3CS hybrid formation (Chapter 2), the 
RNA templates were hybridized with their complementary strands in the stabilizing Tris buffer 
conditions. Each purified complementary strand was added to their corresponding RNA templates 
in stoichiometric ratios that favored hybrid formation and self-assembly of the putative siRNA 
nanostructures (Figure 3.3) in annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5–
8.0, 13-15 μL). Hybridization and self-assembly were promoted by heating the RNA templates 
and their complementary sequences at 90 ºC (5-10 min) followed by slow cooling to room 
temperature (22 ºC) for 1 h, and overnight storage at 4 ºC. siRNA hybridization was confirmed by 
a native, non-denaturing 16% polyacrylamide gel electrophoresis (PAGE). In this assay, (Figure 
3.4) the lower molecular weight templates (linear, V- and Y-shape RNA) migrated fastest on the 
gel and were found to be equivalent to the anticipated migration of the 23-50bp RNA ladder. The 
V-and Y-shaped RNA templates hybridized to their complementary RNA single strands (Figure 
3.4, lanes 10,11 and lanes 8,9 respectively) migrated slower on the gels, with electrophoretic 
mobilities which were found to be comparable to the migration of the 30-50bp RNA ladder (V-
shape siRNA hybrids, lanes 10,11) and the 150-300bp RNA ladder (Y-shape siRNA hybrids, lanes 
8,9). The self-assembled V- (Figure 3.4, lanes 4-7) and Y-shape (Figure 3.4, lanes 2, 3) siRNA 
hybrids migrated the slowest on the gels. The self-assembled V-shape siRNA hybrids (lanes 4,5) 
migrated with similar electrophoretic mobility on gel when compared to the V-shape siRNA 
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hybrids formed with their complementary linear RNA sequences (lanes 10,11). The siRNA hybrid 
combinations formed with multiple Y- and V-RNA templates (lanes 2,3 and 6,7, respectively) 
were found to be ≥300bp RNA ladder suggesting the formation of higher-ordered siRNA 
nanostructures.
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Figure 3.4 siRNA self-assembly. Native, non-denaturing 16% PAGE of self-assembled Y- (lanes 
2-3), V-shape (lanes 4-7) siRNA hybrids, Y-shape RNA templates hybridized to linear 
complementary RNA sequences (lanes 8, 9), V-shape RNA templates hybridized to linear 
complementary RNA sequences (lanes 10, 11), linear siRNA (lane 12) along with Y-shape (lane 
13), V-shape (lane 14) and linear (lane 15) RNA templates. The RNA ladder (23-500bp) was used 
to track the relative sizes of the siRNA hybrids on the gel (lanes 1). 
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3.5.2 Structural Analysis of siRNA Hybrids by Transmission Electron Microscopy 
In order to determine the sizes and shapes of the siRNA hybrids detected on native PAGE, 
a transmission electron microscopy (TEM) study was conducted. Interestingly, the TEM images 
of the complementary hybrid V- and Y-shaped siRNAs revealed nanostructures of well-defined 
geometries and size distributions (Figure 3.5).  For example, the siRNA hybrid A11:S11 was 
found to self-assemble into circular and rectangular nanostructures having size distributions of 60-
100 nm (Figure 3.5A). Comparatively, the TEM image of the siRNA hybrids A12:S12 self-
assembled to form squares (60-80 nm) with a few elongated (80-110 nm) rectangular shape 
nanostructures (Figure 3.5B). The nanoparticle formulation formed from hybridizing three 
complementary V-shape RNA templates, namely, A11:A2S1:S12, self-assembled into triangle-
shaped siRNA nanostructures having mostly smaller size distributions of 10-50 nm (Figure 3.5C). 
Pushing the boundaries of siRNA self-assembly, the V-shape templates composed of 
A11:A2S1:S12:A12 generated pentagons of sizes 90-100 nm, squares and rectangles of sizes 
ranging from 60-80 nm and 100-120 nm, respectively, (Figure 3.5D). The siRNA hybrid formed 
from the Y-shape RNA templates, A123:S123, formed hexagonal shaped nanostructures ranging 
in sizes from 80-120 nm (Figure 3.5F). Comparatively, the siRNA hybrid A111:S111 was 
uniquely shown to self-assemble into porous spheres, with diameters ranging from ~20 - ~110 nm 
and with pore sizes as small as 3- 30 nm (Figure 3.5E). This novel type of RNA nanomaterial may 
be especially useful in small molecule encapsulation and release applications, such as those 
belonging to the stable RNA nanoparticles that have been used in drug delivery for cancer 
therapy.62 
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Figure 3.5 Sizes and shapes of siRNA nanostructures. TEM images and particle size distribution 
plots of (A) V-shape siRNA hybrids A11:S11, (B) V-shape siRNA hybrids A12:S12, (C) V-shape 
siRNA hybrids A11:A2S1:S12, (D) V-shape siRNA hybrids A11:A2S1:S12:A12, (E) Y-shaped 
siRNA hybrids A111:S111, and (F) Y-shaped siRNA hybrids A123:S123. 
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3.5.3 Thermal Denaturation (Tm) analysis of siRNA Hybrids by UV-Spectroscopy 
siRNA hybrid stabilities were measured by thermal denaturation (Tm). The siRNA hybrids 
based on the V-shape RNA templates were found to be very stable, with high Tm values obtained 
for the A11:S11 (Tm = 84 ºC) and A12:S12 (Tm = 78 ºC), Figure 3.6. The V-shaped RNA templates 
hybridized with their complementary linear strands showed good thermal stabilities (A11:S1:S1, 
Tm = 76 ºC and A12:S1:S2, Tm = 77 ºC). Similarly, the siRNA hybrids, A111:S111 and A123:S123, 
based on the Y-shape RNA templates were also found to be stable, Tm = 69 ºC and Tm = 63 ºC, 
respectively. The Y-shaped RNA template hybridized to its complementary linear RNA strands 
formed siRNA hybrids which maintained good thermal stabilities (A111:S1:S1:S1, Tm = 62 ºC and 
A123:S1:S2:S3, Tm = 68 ºC), Figure 3.6.  
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Figure 3.6. Thermal denaturation of V- and Y-shaped siRNAs. All sample hybrids were prepared 
by annealing equimolar quantities (0.75 µM) of antisense V-shaped (A) or Y-shaped (B) RNA to 
their complementary single or V- or Y-shaped RNA template strands. Samples were hybridized in 
anealing buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5–8.0, 13-15 μL)  by pre-heating 
at 95 ºC followed by slow cooling to room temperature over 1 h and overnight storage at 4 ºC prior 
to Tm analyses. Before running Tm, all samples were diluted in annealing buffer (1 mL) and the Tm 
analyses were observed at 260 nm between temperatures of 5-95 ºC. 
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3.5.4 Secondary Structural Analysis of siRNA Hybrids by Circular Dichroism Spectroscopy 
Circular dichroism (CD) spectroscopy was used to explore whether the siRNA 
nanostructures maintained the prerequisite A-type helix geometry for RNAi applications.63  The 
linear siRNAs displayed typical CD profiles for A-form helices, with a minimum peak at 240 nm 
and a broad maximum in between 250-290 nm.64 In the case of the self-assembled V- and Y-shape 
siRNA hybrids (Figure 3.7), the A-type broad maximum and minimum bands were observed 
between 250-290 nm and 240 nm, respectively, albeit with a decrease in the amplitudes of the 
molar ellipticities at these characteristic wavelengths. Despite this change, the self-assembled V- 
and Y-shape siRNA hybrids maintained CD signatures that were consistent with the A-form RNA 
helix. Taken altogether, the siRNA hybrids were found to maintain thermally stable, A-type helices 
within their higher-ordered nanostructure formulations making them promising candidates for 
their applications in RNAi nanotechnology. 
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Figure 3.7 Circular dichroism spectroscopy of V- and Y-shaped siRNAs. All hybrid siRNA 
samples were prepared by annealing equimolar quantities (0.75 nM) of antisense V-shaped (A) or 
Y-shaped (B) RNA templates with their complementary linear or V- or Y-shaped RNA sequences. 
Samples were hybridized in annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5–
8.0, 13-15 μL)  by pre-heating at 95 ºC (3-5 min) followed by slow cooling to room temperature 
over 1 h and overnight storage at 4 ºC prior to CD analyses. All samples were diluted in annealing 
buffer (1 mL) and the CD analysis was observed from 205-310 nm. 
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3.5.5 Transfection Optimization of siRNA Hybrids 
Prior to our RNAi screen, siRNA transfections were optimized within the GRP78 
overexpressing AN3CA endometrial cancer cell line (ATCC® HTB-111™).43,44,65-69 The linear, 
A1:S1, and the Y-shape, A123:S1:S2:S3 GRP78-targeting siRNAs were selected as test samples 
along with a non-specific (NS) RNA control. The benchmark transfection reagents, Lipofectamine 
2000™, siLentFect™ and Lipofectamine RNAiMAX™ were tested for their transfection 
efficiencies according to the manufacture’s protocol. Briefly, the transfection reagents (2.5-7 µL) 
were mixed with the siRNAs (15 and 30 nM) for 20 min at room temperature (22 ºC) and then 
added to the AN3CA cell culture which was incubated at 37 ºC for 72 h. Cell images were collected 
periodically during the incubation period and revealed the greatest extent of cell growth inhibition 
for the RNAiMAX-mediated siRNA transfections (Figure 3.8A). The enhanced efficiency of the 
RNAiMAX transfections was also supported by the most pronounced GRP78 knockdown effect 
(>90%) as detected by western blot (Figure 3.10), which also led to the most significant cell death 
response (35-55%) according to a cytotoxic lactate dehydrogenase (LDH) release assay (Figure 
3.8D).70 The Y-shape siRNA hybrids, A123:S1:S2:S3, were found to be more active than the linear 
siRNA control, A1:S1, exhibiting a greater GRP78 knockdown effect (>97 % vs. 90 %) which 
translated to a stronger inhibition of the AN3CA cells’ growth (>99% vs. ~30 %) which ultimately 
led to a more pronounced cell death effect (58% vs. 32 %) at 30 nM and over a three day incubation 
period (Figures 3.8-3.10). The cells images of the transfected AN3CA cells obtained from the 
Incucyte™ clearly showed that the Y-shape siRNA (A123:S1:S2:S3) treated cells inhibited cell 
growth and the accumulation of cell debris during the incubation time was also observed in 
comparison to the linear nonspecific siRNA control (Figure 3.9). The anti-cancer effects of the 
siRNAs correlated with silencing of GRP78 activity according to western blot (Figure 3.10). 
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These results have effectively served to validate the potent anti-cancer effects of the 
multifunctional Y-shape siRNA, paving the way for a vigorous screening assay for evaluating the 
SARs of the GRP78-targeting siRNAs within the AN3CA EC cells. 
 
 
Figure 3.8 Optimization of siRNA transfections in AN3CA cells. The transfection efficiencies of 
the siRNAs, (NS, A1:S1 and A123:S1:S2:S3, 15 nM and 30 nM) using (A) Lipofectamine® 2000, 
(B) siLentFect™ and (C) RNAiMAX™ transfecting reagents were followed in the Incucyte™ (0 – 
70 h) to obtain the AN3CA cell growth curves. (D) LDH release assay following siRNA 
transfections. Cell viability of AN3CA cells was measured by the % LDH released in the media 
and normalized according to the NS RNA treatment. 
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Figure 3.9 Cell growth images of the treated AN3CA EC cells. Images captured from the 
Incucyte™ represent treated cells (0 and 72 h) with the scrambled NS RNA control (30 nM) and 
the Y-shape siRNA composed of A123:S1:S2:S3 (30 nM) transfected with RNAiMAX™ (7 µL). 
AN3CA cells exhibited proliferative growth in the case of the NS RNA treatment, whereas, the Y-
shape siRNA elicited growth inhibition and apparent cell death from the noticeable debris 
following 72 h incubation. 
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 Figure 3.10 Western blot of the total GRP78 levels following siRNA transfections. siRNAs 
(A1:S1 and A123:S1:S2:S3, 15 and 30 nM) were transfected with RNAiMAX™ within the 
AN3CA cells. Following incubation (72 h), cells were lysed, protein concentrations were 
determined within the lysates, separated by SDS PAGE, transferred to a PVDF membrane which 
was blocked, immunoblotted with anti-GRP78 pAb and detected by chemiluminescence with 
HRP-conjugated secondary Ab. The loading control, GAPDH, was used to normalize the detected 
bands for quantitative densitometry using NIH imager (ImageJ). 
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3.5.6 24-siRNA Screen in the AN3CA EC Cells  
Our hybridization and self-assembly approach has enabled the preparation of a small 
library of twenty-four (24) siRNA samples for evaluating their SARs in EC. RNAiMAX™ 
transfections of 24 siRNA samples at single doses (15 nM) within the AN3CA cells were evaluated 
over a three-day incubation period. Cell growth data obtained from the Incucyte™ (24-72 h) 
revealed the most significant growth inhibition (70-95 %) for the multifunctional siRNA 
nanostructures, while the control linear siRNAs and the NS RNA samples exhibited modest effects 
(5–50 %) on the growth of the AN3CA cells (Figure 3.11A). The western blots confirmed the 
anticipated GRP78 knockdown effects, with the siRNAs based on the V- (eg. A12:S1:S2) and Y-
shape (eg. A123:S123) templates triggering the most potent responses (>95%) (Figure 3.11B). 
Interestingly, the Y-shape siRNAs targeting three different GRP78 mRNA sites (A123:S1:S2:S3 
and A123:S123) produced the most marked effects on GRP78 knockdown (>95%) when compared 
to the linear siRNA controls targeting single (A1:S1, 15%), double (A1:S1 + A2:S2, 80%) and 
triple (A1:S1 + A2:S2 + A3:S3, 85%) oncogenic GRP78 mRNA sites. Moreover, these synergistic 
responses were also observed when monitoring the levels of the cleaved 85-kDa protein poly 
(ADP-ribose) polymerase (Cl-PARP), a molecular marker of apoptosis in cells (Figure 3.11B).71 
For example, the potent Y-shape siRNA (A123:S1:S2:S3) demonstrated significant GRP78 
knockdown and growth inhibition (>90%, 15 nM), with notable increases in Cl-PARP levels 
(~50%). Comparatively, the linear control siRNAs (A1:S1 + A2:S2 + A3:S3) resulted in less 
(~30%) Cl-PARP expression (Figure 3.11C). Taken altogether, the multifunctional siRNAs 
stimulate synergistic anticancer responses in EC. These effects supersede those seen by the control 
siRNAs, even when added in combination, making the siRNA nanostructures more promising 
candidates for RNAi screening and cancer gene therapy applications. 
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Figure 3.11 24-siRNA screen. (A) AN3CA cell growth curves following 24 siRNA transfections. 
siRNAs (15 nM) were transfected with RNAiMAX™ (7 µL) in endometrial AN3CA cancer cells 
and incubated (37 ºC, 72 h). Cell growth curves were obtained periodically (24 – 72 h) within the 
Incucyte™ and normalized according to the NS RNA (B) Western blots of the GRP78 knockdown 
and Cl-PARP levels following siRNA treatment. (C) The GRP78 (% knockdown) and Cl-PARP 
(% increase) levels were normalized according to GAPDH and quantified with respect to the NS 
RNA. 
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3.5.7 Transfection of the siRNA Leads 
From the single dose 24 sample siRNA screen, four (4) V- (A12:S1:S2 and A12:S12) and 
Y-shape (A123:S1:S2:S3 and A123:S123) siRNA nanostructures were selected to validate the 
potency of their RNAi activity relative to their corresponding linear NS RNA and the siRNA 
(A1:S1, A2:S2, A3:S3, A1S1, A1:S1 + A2:S2, A1:S1 + A2:S2 + A3:S3) controls (Figure 3.12). 
The siRNA hybrids which exhibited the most pronounced anticancer effects, based on GRP78 
knockdown, Cl-PARP levels and cell growth inhibition in our siRNA screen were selected as 
leads. As anticipated, the self-assembled siRNAs inhibited the AN3CA cells’ growth to about a 
40% greater extent relative to the controls (Figure 3.12A). A LDH release assay confirmed the 
cytotoxicities of the siRNA formulations, even at low dosages (5 nM), with the Y-shape 
A123:S1:S2:S3 siRNA exhibiting the most lethal (~10%) effects (Figure 3.12B). Moreover, 
western blot validated their potent GRP78 knockdown efficiencies, with ≥80% knockdown 
observed for the V- and Y-shape siRNA hybrids, while the linear controls exhibited at most ~75% 
GRP78 knockdown when added in combination (Figure 3.12C and D). Western blot also 
confirmed that the Cl-PARP levels indicative of apoptosis were observed at significantly increased 
levels in the cases of the V-shape (A12:S1:S2, ~75% and A12:S12, ~65%) and the Y-shape 
(A123:S1:S2:S3, ~77% and A123:S123, ~69%) siRNAs relative to their linear controls (~10- 
~65%). Interestingly, a direct correlation was observed in between GRP78 knockdown and 
increased levels of Cl-PARP indicating that GRP78 knockdown may be directly contributing to 
apoptosis in the AN3CA cells. Taken altogether, this study unveils the potent and long-lasting 
anticancer activities of the V- and Y-shape GRP78-targeting siRNA hybrids within the AN3CA 
EC cells at exceptionally low dosages (5 nM) and for an extended duration of action (72 h).  
Furthermore, these new siRNA motifs may be developed into multi-functional probes for 
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screening the influence of multiple oncogene targets on cancer cell biology and for enhancing the 
gene therapy effects within malignant tumors. 
 
 
 
Figure 3.12 Biological evaluation of the siRNA leads. (A) The AN3CA cell growth curves (0 – 
66 h) obtained from the Incucyte™ following RNAiMAX™ (7 µL) transfections of the siRNAs 
(5 nM). (B)  LDH release assay following siRNA transfections. The % LDH released was 
measured for the siRNAs and normalized according to the NS RNA. (C) Western blot of the total 
GRP78 and Cl-PARP levels following siRNA transfections. The loading control, GAPDH, was 
used to normalize the detected bands for quantitative densitometry using NIH imager (ImageJ). 
(D) The % GRP78 knockdown and the % Cl-PARP levels were normalized according to the NS 
RNA control and quantitated following densitometry of the western blot. The linear (r2 = 0.9243) 
correlation diagram in between the % GRP78 knockdown and the % Cl-PARP levels is provided 
as an inset. All experiments were replicated in triplicates with average values presented with their 
standard deviations about the mean. Statistical analyses produced error bars with acceptable 
variance ±SEM; N = 3, p < 0.05. 
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3.5.8 RNAi Screening of the GRP-Targeting siRNAs 
  The GRP overexpressing human cervical HeLa (ATCC® CCL-2™),49 endometrial 
AN3CA44,68,69 and breast MDA-MB-231 (ATCC® HTB-26™)28 cancer cells in addition to a non-
tumorigenic lung fibroblast MRC5 (ATCC®-CCL-171™)72 cell line displaying normal GRP 
function were used as representative models to explore the influence of the glucose regulated 
chaperones, GRP-75, 78 and 94 on cell viability (Figures 3.13-3.16). The linear, V- and Y-shape 
siRNA hybrids respectively targeting single, double and all three GRPs were used as molecular 
probes for exploring cancer cell biology in our RNAi screening strategy (Table 3.2). The linear 
GRP-75, 78 and 94 siRNAs, used in combination demonstrated notable (20-90%) knockdown of 
GRP expression which translated to modest effects on cell growth inhibition (10-30%) and cell 
death (30-40%) in all cell lines tested. The V-shape siRNA hybrids targeting double chaperones 
(GRP7578, GRP7594 and GRP7894) showed sequence specific knockdown in all cell lines (20-
95%) with varied effects on the expression levels of the non-targeted chaperone. For example, 
within the AN3CA cells, GRP-78 and 94 knockdown had little influence on the expression levels 
of GRP75, whereas GRP-75 and 94 knockdown led to a significant (40%) reduction in the GRP78 
expression levels. Similar trends were delineated across different cell lines. For example, 
knockdown of GRP-75 and 94 led to a decrease in the expression levels of GRP78 within the 
AN3CA cells but not within the HeLa cells, suggesting that the cell lines have varied levels of 
GRP addiction. This assumption was validated by their varied effects on cell growth inhibition 
(30-50%) and death (20-40%). Representatively, GRP-75 and 94 knockdown translated to about a 
2-fold increase in cell death within the HeLa relative to the AN3CA cell lines, underscoring a 
critical role of these chaperones on HeLa cell survival. The most potent anticancer effects were 
observed with the tri-functional Y-shape siRNA targeting GRP-75, 78 and 94. In this case, potent 
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(50-95%) knockdown was observed in all cancer cell lines which translated to significant levels of 
tumor cell cycle arrest (50-80%) and cancer cell death (50-60%). In comparison, the multiple 
GRP78-targeting Y-shape siRNA (A123:S1:S2:S3) triggered only about 10% AC3CA cell death 
whereas the GRP-75, 78 and 94 targeting Y-shape siRNA produced a 5-fold increase (50%) in 
cytotoxicity at low doses of 5 nM. The results observed for the Y-shape siRNA targeting GRP-75, 
78 and 94 supersede the anticancer effects observed from all other siRNA hybrids tested in our 
study and underscores the synergistic influence of compromising chaperome activity in cancer. 
Moreover, GRP knockdown with the GRP-75, 78 and 94 targeting Y-shape siRNA had a more 
pronounced effect on tumor cell growth inhibition (50-80%) and death (50-60%) when compared 
to the control, non-tumorigenic MRC5 cell line which displayed modest growth inhibition (10-
30%) and death (10-20%). These results correlate an addiction of human cancer cells to the 
overexpressed glucose regulated chaperome which may contribute towards cancer treatment 
selectivity.73 Therefore, the self-assembled siRNA hybrids targeting multiple GRPs proved useful 
in screening these important oncogene targets for elucidating their role on cancer cell biology 
while improving siRNA therapeutic efficacy and specificity in cancer. 
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Figure 3.13 Cell Growth Curves. siRNA (5 nM) transfections with RNAiMAX™ (7 µL) in (A) 
MRC5, (B) AN3CA, (C) MDA-MB-231, and (D) HeLa cells were incubated at 37 °C for 72 h. 
Cell growth data was obtained periodically (every 2 h) within the Incucyte™ for 68-72 h, plotted 
and normalized according to the NS RNA. Data representative of three independently conducted 
experiments. 
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Figure 3.14 Western blots of the GRP78, 94 and 75 knockdown following siRNA treatment. 
Western blots showing 5 nM of siRNAs transfection in HeLa (Cervical cancer cells) and MDA-
MB-231 (Breast cancer cells) following 72 h incubation at 37 ºC. The GRP78, GRP94 and GRP75 
(% knockdown) levels were normalized according to GAPDH and quantified with respect to the 
NS RNA. Data represents comparative efficiency of linear siRNAs (GRP78, GRP94, GRP75) and 
Y-shape siRNA (GRP789475). 
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Figure 3.15 RNAi screening. Western blots measuring GRP78, GRP94 and GRP75 (% protein) 
levels following siRNA (5 nM) transfections in normal lung, MRC5, endometrial, AN3CA, breast, 
MDA-MB-231 and cervical, HeLa cancer cells. The GRP78, GRP94 and GRP75 levels were 
normalized according to GAPDH and quantified with respect to the NS RNA. Data represents 
knockdown efficiency of V-shape siRNAs (GRP7894, GRP7875, GRP9475), Y-shape siRNA 
(GRP789475) and the linear siRNAs (GRP78+GRP94+GRP75) added in combination. All 
experiments were replicated in triplicates with average values presented with their standard 
deviations about the mean. Statistical analyses produced error bars with acceptable variance 
±SEM; N = 3, p < 0.05. 
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Figure 3.16 LDH Release Assay. The % LDH released was measured following transfections of 
all treated cell lines (MRC5, AN3CA, MDA-MB-231 and HeLa). The LDH levels were 
quantitated and normalized according to the NS RNA. All experiments were replicated in 
triplicates with average values presented with their standard deviations about the mean. Statistical 
analyses produced error bars with acceptable variance ±SEM; N = 3, p < 0.05. 
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3.5.9 Serum Stability of the siRNA Hybrids 
  
The serum stability of selected siRNAs was next evaluated in fetal bovine serum (FBS).  The linear 
(A1:S1), V- (A12:S12) and Y-shaped (A123:S1:S2:S3) siRNAs were hybridized in annealing 
buffer, treated with 10% FBS and incubated at 37 °C for 48 h. Periodically, aliquots were collected, 
concentrated and suspended in gel loading buffer, for 16% native PAGE analyses (Figure 3.17). 
As expected, the linear siRNA completely degraded, even after shorter incubation times of four 
hours. These results confirm the limited duration of action and therapeutic index of the native 
siRNAs that are readily degraded by nucleases present in serum.36 In comparison, the siRNA 
nanostructures were shown to quickly (4 h) disassemble into shorter hybrid sequences and also 
into their native templates upon FBS treatment. In these cases, only partial degradation was 
observed even after 48 h treatment. In a separate FBS stability assay, (Figure 3.18 and 3.19) the 
linear (A1), V-shape (A12) and Y-shape (A123) RNA templates were completely degraded after 
24 h treatment. However, the higher-order siRNA hybrids formed from the V- and Y-shape RNA 
templates (A12:S12, A12:S1:S2 and A123:S123, A123:S1:S2:S3, respectively) were found to 
undergo partial degradation after a 48 h incubation period. These results confirm that the higher-
order siRNA nanostructures formed from the V-and Y-shape RNA templates impart partial 
stability to the nucleases present in serum which likely contributes to their prolonged duration of 
action relative to the linear siRNA hybrids. These results are consistent with the observed serum 
stability of other RNA nanostructures, suggesting that higher order structure formation may 
contribute to enhanced serum stability.75 Moreover, site specific or gapmer modifications to the 
siRNA sequences have also been shown to improve resistance towards nuclease degradation, and 
may be incorporated to further enhance serum or plasma stability while retaining potent silencing 
activity.76 
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Figure 3.17 siRNA FBS stability assay (1).  The native PAGE (16%) analyses of the serum 
stability of the linear siRNA (A1:S1) compared with the V- (A12:S1:S2 and A12:S12) and Y-
shaped (A123:S1:S2:S3) siRNA nanostructures over 48 h in 10% FBS. 
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Figure 3.18. siRNA FBS stability assay (2).  The native PAGE (16%) analyses of the serum 
stability of the Y-shape, V-shape and linear siRNA templates compared with the self-assembled 
V- (A12:S12) and Y-shaped (A123:S123) siRNA nanostructures over 48 h in 10% FBS. The RNA 
ladder (23-500bp) was used to track the relative sizes of the hydrolyzed siRNA components on the 
gels. 
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Figure 3.19. siRNA FBS stability assay (3).  The native PAGE (16%) analyses of the serum 
stability of the Y-shape, V-shape and linear siRNA templates compared with the self-assembled 
V- (A12:S1:S2) and Y-shaped (A123:S1:S2:S3) siRNA nanostructures over 48 h in 10% FBS. The 
RNA ladder (23-500bp) was used to track the relative sizes of the hydrolyzed siRNA components 
on the gels. 
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3.6 CONCLUSIONS 
We have effectively demonstrated the rational design and applications of RNA templates 
in the self-assembly of discrete, higher order siRNA nanostructures for RNAi screening and cancer 
gene therapy applications. The novel siRNA nanostructures created in this study have expanded 
the repertoire of multifunctional siRNAs. They were shown to adopt unique shapes and well 
defined structures according to TEM imaging. Moreover, thermal denaturation and CD 
spectroscopy were respectively used to confirm the prerequisite siRNA hybrid stabilities and A-
form helices for invoking RNAi activity. In endometrial cancer, the higher-order siRNA hybrids 
were found to trigger synergistic anticancer effects, which surpassed those observed with the linear 
siRNAs. The V- and Y-shape siRNA hybrids induced potent (>95%) GRP78 knockdown, which 
inhibited tumor cell growth (35-55%) and stimulated programmed cell death according to the 
release of LDH and the increase in the 85-kDa Cl-PARP fragment, a molecular marker of 
apoptosis. In an RNAi screen across a panel of GRP overexpressing cancer cell lines and a non-
tumorigenic control displaying regulated levels of GRP, the multi-functional V- and Y-shape 
siRNAs targeting GRP-75, 78 and 94 displayed synergistic anticancer effects which superseded 
their linear controls or the V- and Y-shape siRNAs targeting GRP78 alone. The RNAi screen also 
revealed the influence of GRP activity on cell viability. The GRP overexpressing cancer cells were 
sensitized to GRP-75, 78 and 94 knockdown resulting in greater tumor cell cycle arrest and 
cytotoxicity relative to the non-tumorigenic control. These studies revealed a greater dependence 
of human cancer cells to the overexpressed glucose regulated chaperome which was found to 
contribute to cancer treatment selectivity. A FBS serum stability assay provided preliminary 
mechanistic insights into the anticancer activity of the siRNA hybrids. In these experiments, the 
linear siRNAs and the non-hybridized RNA templates were found to degrade in the presence of 
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serum nucleases. Whereas, the siRNA nanostructures were found to undergo only partial 
degradation after a 48 h incubation period in 10% FBS. Therefore, the higher-order V- and Y-
shape siRNA hybrids were found to confer greater resistance towards degradation in serum that 
may likely contribute to the long-lasting oncogene knockdown and anticancer effects observed in 
our study. Additional mechanistic studies are currently underway to elucidate the complete 
mechanism of action of the novel siRNA hybrids. In conclusion, these novel siRNA motifs 
encompass a new class of bio-probes for studying RNAi activity in cancer and also for screening 
important (single or multiple) oncogene targets for successful applications in cancer gene therapy. 
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CHAPTER 4: CONCLUSIONS AND CONTRIBUTIONS TO 
KNOWLEDGE 
4.1 CONCLUSIONS AND CONTRIBUTIONS TO KNOWLEDGE MADE IN THIS THESIS 
4.1.1 Prerequisites for the Self-Assembly of Stable RNA Three Component Systems (3CS)  
RNA nanotechnology has emerged as a powerful tool in the study of structure and function 
of biologically relevant RNA. In order to gain in-depth knowledge on the RNA hybridization and 
self-assembly requirements, Chapter-2 describes the influence of RNA sequence composition, 
length and buffer on RNA self-assembly into stable 3CS. This study involved the solid-phase 
synthesis of template RNA strands (RNAT15, RNAT20 and RNAT30) and its complementary RNA 
sequences (RNAC15, RNAC23) (Table 2.1). The synthesized RNAs were obtained in high crude 
yields (≥84%) and purities (≥98%) according to UV-Vis spectroscopy and IP-RP-HPLC. The 
identity of the RNA sequences were confirmed by molecular weight analysis using ESI-MS. The 
hybridization properties were investigated by native PAGE in different buffer conditions (Figure 
2.8). The 30nt RNA template RNAT30 displayed the most stable RNA hybrid 3CS in Tris buffer, 
with the complementary RNA sequences (RNAC15, RNAC23).  Thermal denaturation indicated the 
thermal stabilities of the RNA 3CS, in which the lengthier template provided the most stable hybrid 
structures (RNAT30>RNAT20>RNAT15) in each buffer condition (Figure 2.9). The double 
transitions (Tm: 45 ºC and 77 ºC), indicative of denaturation of two hybrid strands confirmed that 
the lengthy 30 nt RNA template, RNAT30, provided the highest thermal stability in Tris buffer. 
The secondary structure analysis of the RNA hybrid 3CS were studied by CD spectroscopy. The 
pre-requisite A-type RNA helical trajectory was confirmed for all RNA hybrid 3CS (Figure 2.10), 
in Tris buffer which maintained the most pronounced CD signature, asserted by absorbance 
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minima and maxima. Taken altogether, the chemical and biophysical characterization studies 
revealed the most stable helical RNA hybrid 3CS with the 30nt RNA template and with the 
complementary 15 nt and 23 nt RNA sequences in Tris buffer conditions. These findings are not 
only important for understanding the requirements for RNA hybridization and self-assembly, but 
also for promoting higher-order RNA structures that have biological importance and therapeutic 
relevance for cancer gene therapy applications (Chapter 3).  
4.1.2 siRNA Nanostructures for Cancer Gene Therapy 
 In the realm of RNA nanotechnology, siRNA based nanostructures provide particular 
promise in RNAi-mediated cancer gene therapy applications. As discussed in Chapter 1, RNA 
nanotechnology favors the self-assembly of multiple RNA motifs within a single molecular 
structure that may synergize the therapeutic responses. The self-assembly of RNA requires the 
careful design of template sequences that may self-assemble with complementary sequences into 
higher-order structures with improved biological function and enhanced chemical and thermal 
stabilities. The optimization studies described in Chapter 2 for the stable self-assembly of RNA 
3CS provided a platform for the design of novel siRNA nanostructures that proved to be useful in 
screening important oncogene targets while potentiating the cancer gene therapy effects. In 
Chapter 3, a new class of siRNA nanostructures based on linear, V-shape and Y-shape RNA 
templates were self-assembled with their complementary RNA sequences to afford higher-order 
RNA structures of well-defined sizes and shapes (Figures 3.3 and 3.5). The synthesis of V-shape 
and Y-shape RNA templates were completed with the incorporation of the ribouridine branchpoint 
synthon. The siRNAs were synthesized in good crude yields (≥62%) and purified using IP-RP-
HPLC to obtained sequence purities (≥97%) whose identities were confirmed by ESI-MS, (Table 
3.2).  
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The RNA templates were hybridized with their complementary sequences in Tris annealing 
buffer using stoichiometric ratios that promoted the self-assembly of the putative siRNA 
nanostructures, (Figure 3.3). A native PAGE was used to confirm hybridization and self-assembly 
into higher-order structures, (Figure 3.4). The sizes and shapes of the siRNA hybrids were 
elucidated by TEM imaging. The images revealed unique structural geometries for the self-
assembled V- and Y-shape siRNA hybrids into genetically encoded circles, triangles, squares, 
rectangles, pentagons, hexagons and porous sphere-type structures with varying pore sizes 15-160 
nm (Figure 3.5). Moreover, thermal denaturation and CD studies revealed high thermal stability 
(Figure 3.6) and the A-type helical geometries (Figure 3.7), of the siRNAs nanostructures for 
RNAi activity. 
The RNAiMaxTM mediated transfection efficiency was initially optimized (Figure 3.8-
3.10) within the GRP78 overexpressing AN3CA endometrial cancer cells. Following optimization 
of the transfection procedure, a 24 sample siRNA screen (Figure 3.11) was conducted in order to 
identify the most potent siRNA leads. The lead siRNAs produced the most pronounced GRP78 
knockdown and apoptosis of the AN3CA cancer cells. More specifically, the lead Y-shape siRNA 
targeting three different sites of oncogenic GRP78 mRNA showed the greatest GRP78 knockdown 
efficiency (>90%) which translated into notable cell growth inhibition (~40%) and cell death 
effects (~10%) at low (5 nM) siRNA doses (Figure 3.12).  
 Furthermore, this study also revealed the influence of multiple GRPs (GRP-75, 78 and 94) 
on MDA-MB-231 (breast cancer), HeLa (cervical cancer), AN3CA (endometrial cancer) and 
MRC5 (non-tumorigenic lung cells) cells’ survival. The multi-chaperone (GRP-75, 78 and 94) 
targeting V- and Y-shape siRNA hybrids revealed synergistic effects of silencing the GRP 
chaperome in cancer. More specifically, cancer cells were found to be more profoundly affected 
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by the siRNAs relative to the control, non-cancerous cells (Figure 3.14-3.16). Therefore, the self-
assembled siRNA hybrids targeting multiple GRPs may provide specific and more potent 
anticancer activities. These findings are not only important for enhancing the gene therapy effects 
of siRNAs but also for screening the influence of oncogene targets on the progression of cancer.  
Finally, the stability of linear, V- and Y-shape siRNA hybrids were assessed in 10% FBS. 
Interestingly, the linear hybrid siRNA was completely degraded within 4 h post treatment while, 
the V- and Y-shape siRNA hybrids were shown to disassemble into the native RNA template 
strands, without further degradation, even after 48 h treatment (Figure 3.17). These results are 
also important, as they provide mechanistic insights into the prolonged (72 h) activity of the siRNA 
hybrids. In these cases, the template V- and Y-shape RNAs may contribute to the potent RNAi 
effects observed in cancer cells.  Future work will be dedicated to study the complete mechanism 
of action while evaluating the efficacy of the siRNA nanostructures in mice tumor xenograft 
models. 
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Figure A1. RP IP LC/MS analysis of V-shape A11 RNA (9) 
 
 
9) A11:    
         2'3'-UCA CAA CCU UCU AAG ACU A-5’                    MS.  Calc.      12266.4 g/mol  
                                    rU                                                                                                    Found    12266.6 g/mol 
         3'5'-AUC AGA AUC UUC CAA CAC U-3'     
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Figure A2. RP IP LC/MS analysis of V-shape A12 RNA (10) 
 
 
10) A12:   
2'3'-CCU CGC GUA ACU AUG AUC U-5'               MS.  Calc.         12275.4 g/mol 
          rU                                                                                                  Found      12277.0 g/mol     
3'5'-AUC AGA AUC UUC CAA CAC U-3' 
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Figure A3. RP IP LC/MS analysis of V-shape S11 RNA (11) 
 
 
11) S11:   
       2'3'-UAG UCU UAG AAG GUU GUG A-5'               MS.  Calc.        12574.5 g/mol           
           rU                                                                                                Found      12575.5 g/mol     
   3'5'-AGU GUU GGA AGA UUC UGA U-3' 
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Figure A4. RP IP LC/MS analysis of V-shape S12 RNA (12) 
 
 
12) S12:    
    2'3'-AGA UCA UAG UUA CGC GAG G-5'                MS.  Calc.       12595.6 g/mol  
                                         rU                                                                                                     Found     12596.2 g/mol      
    3'5'-AGU GUU GGA AGA UUC UGA U-3' 
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Figure A5. RP IP LC/MS analysis of V-shape A2S1 RNA (13) 
 
 
13) A2S1   
2'3'-UAG UCU UAG AAG GUU GUG A-5'               MS.  Calc.       12429.7 g/mol         
             rU                                                                                                 Found     12430.6 g/mol 
3'5'-UCU AGU AUC AAU GCG CUC C-3’ 
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Figure A6. RP IP LC/MS analysis of V-shape A1S1 RNA (14) 
 
 
14)   A1S1   
2'3'-UAG UCU UAG AAG GUU GUG A-5'                  MS.  Calc.       12421.2 g/mol        
             rU                                                                                                    Found     12421.6 g/mol 
3'5'-AUC AGA AUC UUC CAA CAC U-3' 
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Figure A7. RP IP LC/MS analysis of Y-shape A111 RNA (15) 
 
 
15) A111: 
                        2'3'-UCA CAA CCU UCU AAG ACU A-5'       MS.  Calc.  18278.0 g/mol 
 5'-AUC AGA AUC UUC CAA CAC U-3'5'-U                                                                         Found 18278.4 g/mol 
                       3'5'-AUC AGA AUC UUC CAA CAC U-3' 
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Figure A8. RP IP LC/MS analysis of Y-shape A123 RNA (16) 
 
 
16) A123: 
                     2'3'-CCU CGC GUA ACU AUG AUC U-5'        MS.  Calc.     19975.2 g/mol  
5'-GUA ACA ACU GCA UGG GUA ACC UUC-3'5'-U                                                     Found   19975.8 g/mol   
                3'5'-AUC AGA AUC UUC CAA CAC U-3' 
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Figure A9. RP IP LC/MS analysis of Y-shape S111 RNA (17) 
 
 
17) S111: 
                                                               2'3'-UAG UCU UAG AAG GUU GUG A-5'     MS.  Calc.   18739.2 g/mol  
5'-AGU GUU GGA AGA UUC UGA U-3'5'-U                                                                         Found 18740.6 g/mol 
         3'5'-AGU GUU GGA AGA UUC UGA U-3' 
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Figure A10. RP IP LC/MS analysis of Y-shape S123 RNA (18) 
 
 
18) S123: 
                                                        2'3'-AGA UCA UAG UUA CGC GAG G-5'        MS.  Calc.     20531.2 g/mol 
5'-GAA GGU UAC CCA UGC AGU UGU UAC-3'5'-U                                                     Found   20534.0 g/mol 
                            3'5'- AGU GUU GGA AGA UUC UGA U-3' 
